

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



10624-003
(FBP1)

b-TCP2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 9/00, 15/11, A61K 38/53, C07K 16/40, G01N 33/50		A2	(11) International Publication Number: WO 00/34447 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/29371 (22) International Filing Date: 10 December 1999 (10.12.99) (30) Priority Data: 09/210,060 10 December 1998 (10.12.98) US (71) Applicants: SIGNAL PHARMACEUTICALS, INC. [US/US]; 5555 Oberlin Drive, San Diego, CA 92121 (US). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; P.O. Box 4279, 91042 Jerusalem (IL). (72) Inventors: MANNING, Anthony, M.; 12333 Goldfish Court, San Diego, CA 92129 (US). MERCURIO, Frank; 3674 Carmel View Road, San Diego, CA 92130 (US). AMIT, Sharon; Yissum Research Development Company of the Hebrew University of Jerusalem, P.O. Box 4279, 91042 Jerusalem (IL). BEN-NERIAH, Yinon; 5 Mevo Duvdevan, 90805 Zion (IL). DAVIS, Matti; 40 Paliam Street, 97890 Jerusalem (IL). HATZUBAI, Ada; Yissum Research Development Company of the Hebrew University of Jerusalem, P.O. Box 4279, 91042 Jerusalem (IL). LAVON, Iris; 38 Hermon Street, 90805 Mevasseret Zion (IL). YARON, Avraham; 1 Emil Zola, 93107 Jerusalem (IL).		(74) Agents: MAKI, David, J. et al.; Seed And Berry LLP, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-κB			
(57) Abstract Compositions and methods for modulating the activation of nuclear factor κ B (NF- κ B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I κ B α and/or I κ B β . Such compositions may be used for treating diseases associated with NF- κ B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF- κ B

TECHNICAL FIELD

The present invention relates generally to compositions and methods for
5 modulating the activation of nuclear factor κ B (NF- κ B). The invention is more particularly related to agents that modulate ubiquitination of phosphorylated I κ B α and/or I κ B β and to methods for treating diseases associated with NF- κ B activation. Modulating agents encompassed by the present invention include E3 ubiquitin ligases, and portions and variants thereof.

10 BACKGROUND OF THE INVENTION

NF- κ B is a transcription factor that plays a pivotal role in the highly specific pattern of gene expression observed for immune, inflammatory and acute phase response genes, including interleukin 1, interleukin 8, tumor necrosis factor and certain cell adhesion molecules. Like other members of the Rel family of transcriptional
15 activators, NF- κ B is sequestered in an inactive form in the cytoplasm of most cell types. A variety of extracellular stimuli including mitogens, cytokines, antigens, stress inducing agents, UV light and viral proteins initiate a signal transduction pathway that ultimately leads to NF- κ B release and activation.

Important modulators of NF- κ B activation are the inhibitor proteins
20 I κ B α and I κ B β (referred to herein as I κ B), which associate with (and thereby inactivate) NF- κ B in the cytoplasm of nonstimulated cells. Activation and nuclear translocation of NF- κ B occurs following signal-induced phosphorylation of I κ B, which leads to proteolysis via the ubiquitin pathway. For I κ B α , the stimulus-induced phosphorylation at serines 32 and 36 renders the inhibitor a target for ubiquitination at
25 lysines 21 and 22, resulting in degradation. Similarly, phosphorylation of I κ B β at serines 19 and 23 renders the inhibitor a target for ubiquitination at lysine 9. However, the component(s) of the ubiquitin system mediating I κ B recognition have not been identified.

Degradation of a protein via the ubiquitin pathway proceeds by two
30 discrete and successive steps: (a) covalent attachment of multiple ubiquitin molecules to the protein substrate, and (b) degradation of the targeted protein by the 26S proteasome complex. The ubiquitin pathway consists of several components that act in concert and in a hierarchical manner (for reviews, see Ciechanover, *Cell* 79:13, 1994; Hochstrasser, *Curr. Op. Cell. Biol.* 7:215, 1995; Jentsch and Schlenker, *Cell* 82:881,

1995; Deshaies, *Trends Cell Biol.* 5:428, 1995). One such component, a single E1 enzyme, carries out activation of ubiquitin. Several major species of E2 enzymes have been characterized in mammalian cells, plants, and yeast. E2 enzymes probably bind to the ligase E3 (Reiss and Hersko, *J. Biol. Chem.* 265:3685, 1990; Dohmen et al., *Proc. Natl. Acad. Sci. USA* 88:7351, 1991) and it appears that each E2 enzyme can act with one or more E3 proteins (Nuber et al., *J. Biol. Chem.* 271:2795, 1996; Orian et al., *J. Biol. Chem.* 270:21707, 1995; Stancovski et al., *Mol. Cell. Biol.* 15:7106, 1995; Gonen et al., *J. Biol. Chem.* 271:302, 1996).

Only few E3 enzymes (ubiquitin ligases) have been described. Mammalian E3 α (UBR1 in yeast) and E3 β recognize protein substrates via their free N-terminal amino acid residues ("N-end rule"; Varshavsky, *Cell* 69:725, 1992; Hershko and Ciechanover, *Annu. Rev. Biochem.* 61:761, 1992). Cdc53 is probably an E3 involved in targeting phosphorylated G1 cyclins (Willems et al., *Cell* 86:453, 1996). E6-AP is involved in recognition of p53 (Scheffner et al., *Cell* 75:495, 1993), and a series of unique E6-AP homologous proteins have been identified (Huibregtse et al., *Proc. Natl. Acad. Sci. USA* 92:2563, 1995). Ned4 is involved in the degradation of the epithelial Na⁺ channel (Staub et al., *Embo J.* 15:2371, 1996) and RSP5 (NIP1) is involved in tagging the permeases Gap1 and Furl (Hein et al., *Mol. Microbiol.* 18:77, 1995), whereas Pub1 targets Cdc25 (Nefsky and Beach, *EMBO J.* 15:1301, 1996). Several other E3 enzymes that have been recently isolated appear to be involved in the degradation of c-Fos, a subset of muscle proteins, and in the processing of p105, the NF- κ B precursor (Orian et al., *J. Biol. Chem.* 270:21707, 1995; Stancovski et al., *Mol. Cell. Biol.* 15:7106, 1995; Gonen et al., *J. Biol. Chem.* 271:302, 1996). Thus, it appears that the ligases represent a large, mostly unraveled family of enzymes and, except for the mode of recognition of the "N-end rule" ligases (E3 α and E3 β), the recognition motifs of all other known substrates of the ubiquitin system have not been identified.

Accordingly, there is a need in the art for an improved understanding of I κ B degradation via the ubiquitin pathway, and for the identification of modulators of this degradation process for use in treating diseases associated with activation of NF- κ B. The present invention fulfills these needs and further provides other related advantages.

SUMMARY OF THE INVENTION

Briefly stated, the present invention provides compositions and methods for modulating the activation of nuclear factor κ B (NF- κ B) by modulating ubiquitination of phosphorylated I κ B α and/or I κ B β . Within one aspect, the present

invention provides isolated human E3 ubiquitin ligase polypeptides. Such polypeptides may comprise a human E3 ubiquitin ligase sequence as recited in SEQ ID NO:16, or a portion or variant thereof that differs in one or more amino acid substitutions, insertions, deletions and/or additions, such that the polypeptide (a) enhances
5 ubiquitination of phosphorylated I κ B or (b) binds to phosphorylated I κ B and inhibits ubiquitination of phosphorylated I κ B. Within certain embodiments, such a polypeptide may have the sequence recited in SEQ ID NO:16 or a variant thereof that differs in one or more amino acid deletions, insertions or substitutions at no more than 20% of the amino acid residues in SEQ ID NO:16, such that the polypeptide enhances
10 ubiquitination of phosphorylated I κ B. Within further embodiments, such a polypeptide may comprise a portion of a human E3 ubiquitin ligase, or variant of such a portion, wherein the portion binds to phosphorylated I κ B and inhibits ubiquitination of phosphorylated I κ B.

The present invention further provides, within other aspects, isolated
15 polynucleotides that encode a polypeptide as described above. Within certain embodiments, such polynucleotides may encode a portion of a human E3 ubiquitin ligase, or variant of such a portion, as described above. Antisense polynucleotides comprising at least 10 consecutive nucleotides complementary to such a polynucleotide are also provided. Expression vectors comprising such a polynucleotide, and host cells
20 transformed or transfected with such an expression vector, are further provided.

Within further aspects, the present invention provides pharmaceutical compositions comprising a polypeptide or polynucleotide as described above in combination with a physiologically acceptable carrier.

Within other aspects, the present invention provides isolated antibodies,
25 and antigen binding fragments thereof, that bind to a human E3 ubiquitin ligase having a sequence recited in SEQ ID NO:16. Such antibodies may be monoclonal.

Within further aspects, pharmaceutical compositions are provided, comprising an antibody or fragment thereof as described above in combination with a physiologically acceptable carrier.

30 The present invention further provides methods for modulating NF- κ B activity in a patient, comprising administering to a patient a pharmaceutical composition as described above.

Within further aspects, the present invention provides methods for treating a patient afflicted with a disorder associated with NF- κ B activation, comprising
35 administering to a patient a therapeutically effective amount of a pharmaceutical composition as described above, and thereby treating a disorder associated with NF- κ B

activation. Such disorders include inflammatory diseases, autoimmune diseases, cancer and viral infection.

Within further aspects, the present invention provides methods for screening for an agent that modulates NF- κ B activity, comprising the steps of: (a) contacting a candidate agent with a human E3 ubiquitin ligase polypeptide, wherein the polypeptide comprises a sequence recited in SEQ ID NO:16 or a portion or variant thereof that differs in one or more amino acid substitutions, insertions, deletions or additions, such that the polypeptide enhances ubiquitination of phosphorylated I κ B, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent; and (b) subsequently evaluating the ability of the polypeptide to enhance ubiquitination of phosphorylated I κ B, relative to a predetermined ability of the polypeptide to enhance ubiquitination of phosphorylated I κ B in the absence of candidate agent; and therefrom identifying an agent that modulates NF- κ B activity. Candidate agents for use within such screens include, but are not limited to, small molecules present within a combinatorial library.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1D are autoradiograms depicting the results of SDS-PAGE analysis of ubiquitination assays performed in the presence and absence of various I κ B E3 recognition motifs. Unless otherwise indicated, the substrate was an ³⁵S-labelled, HA-tagged I κ B polypeptide that was phosphorylated and NF- κ B complex-associated.

In Figure 1A, lane 1 shows the ubiquitination of an I κ B α polypeptide that contains alanine residues at positions 32 and 36 (S32/36A; SEQ ID NO:13) and lane 2 shows the ubiquitination of a non-phosphorylated wild-type I κ B α polypeptide (SEQ ID NO:12). In lanes 3-14, the ubiquitination substrate was wild-type I κ B α (SEQ ID NO:12). In lane 3, ubiquitination was performed in the absence of ATP; and in lanes 4-14 the reaction was performed in the presence of ATP γ S with (lanes 5-14) or without (lane 4) an I κ B E3 recognition motif or other peptide. The peptides shown are: 400 μ M c-Fos phosphopeptide (ppFos (SEQ ID NO:10), lane 5); 400 μ M serine 32, 36 to alanine substituted I κ B α peptide (pp21S/A (SEQ ID NO:11), lane 6); 40 μ M doubly phosphorylated I κ B α peptide (pp21 (SEQ ID NO:9), lane 7); 400 μ M non-phosphorylated I κ B α peptide (p21 (SEQ ID NO:9), lane 8); 100 μ M singly

phosphorylated I κ B α peptides (ppS32 (SEQ ID NO:9), lane 9; ppS36 (SEQ ID NO:9), lane 10); and 40 μ M shorter, doubly phosphorylated I κ B α peptides (pp19 (SEQ ID NO:8), lane 11); pp15 (SEQ ID NO:7), lane 12; pp11 (SEQ ID NO:6), lane 13; pp7 (SEQ ID NO:5), lane 14).

5 In Figure 1B, the ubiquitination substrate was free wild type I κ B α (SEQ ID NO:12, lanes 1-3) or free S32/36A substituted I κ B α (SEQ ID NO:13, lanes 4-6). The reaction was performed in the absence (lanes 1 and 4) or presence (lanes 2, 3, 5 and 6) of ATP γ S. 40 μ M doubly phosphorylated I κ B α peptide (pp21 (SEQ ID NO:9) was added to the conjugation reaction mixture in the samples shown in lanes 3 and 6.

10 In Figure 1C, the ubiquitination of bulk cellular proteins in HeLa extract is shown. Lane 1 shows the ubiquitination in the absence of ATP, and lane 5 shows the ubiquitination in the presence of ATP. In lanes 3-5, an I κ B E3 recognition motif or other peptide was added: 40 μ M doubly phosphorylated I κ B α peptide (pp21 (SEQ ID NO:9), lane 2); 400 μ M c-Fos phosphopeptide (ppFos (SEQ ID NO:10), lane 3); and
15 400 μ M non-phosphorylated I κ B α peptide (p21 (SEQ ID NO:9), lane 4).

In Figure 1D, the ubiquitination substrate was phosphorylated (lanes 2-7) or non-phosphorylated (lane 1) wild type I κ B β (SEQ ID NO:14). Reactions were performed in the absence (lane 2) or presence (lanes 1, 3-7) of ATP γ S, and with (lanes 4-7) or without (lanes 1-3) an I κ B E3 recognition motif or other peptide. The peptides
20 shown are: 40 μ M doubly phosphorylated I κ B α peptide (pp21 (SEQ ID NO:9), lane 4); 400 μ M c-Fos phosphopeptide (ppFos (SEQ ID NO:10), lane 5); 40 μ M doubly phosphorylated I κ B α peptide (pp19 (SEQ ID NO:8), lane 6); and 400 μ M non-phosphorylated I κ B α peptide (p21 (SEQ ID NO:9), lane 7).

Figure 2 is an autoradiogram depicting the results of an *in vitro*
25 ubiquitin-dependent degradation assay performed using extracts from stimulated HeLa cells. In each lane of the SDS-PAGE, the level of phosphorylated (upper band) and non-phosphorylated (lower band) HA-tagged I κ B α polypeptide (SEQ ID NO:12) following the degradation assay is shown. Lane 1 shows the level of these polypeptides following a degradation assay performed without ATP. In lanes 2-6, ATP was included
30 in the reaction mixture. 40 μ M candidate modulating agents were added to the reactions shown in lanes 3-6: doubly phosphorylated I κ B α peptide (pp21 (SEQ ID NO:9), lane 3); doubly phosphorylated I κ B α peptide (pp19 (SEQ ID NO:8), lane 4); c-Fos phosphopeptide (ppFos (SEQ ID NO:10), lane 5); and non-phosphorylated I κ B α peptide (p21 (SEQ ID NO:9), lane 6).

35 Figure 3A is an autoradiogram depicting the results of SDS-PAGE analysis of ubiquitination assays performed using flow-through fractions of HeLa cell

lysate fractionated over modulating agent columns. In each case, the substrate was a ³⁵S-labelled, HA-tagged IκBα polypeptide (SEQ ID NO:12) that was phosphorylated and NF-κB complex-associated. Lane 1 shows the level of ubiquitination using a non-fractionated extract. In lanes 2-9, the extract was fractionated over a peptide-Sephacrose[®] column. The peptides used were: c-Fos phosphopeptide (ppFos (SEQ ID NO:10), lane 2); serine 32, 36 to alanine substituted IκBα peptide (pp21S/A (SEQ ID NO:11), lane 3); doubly phosphorylated IκBα peptide (pp21 (SEQ ID NO:9), lanes 4-6); and doubly phosphorylated IκBα peptide (pp19 (SEQ ID NO:8), lanes 7-9). In addition, reticulocyte Fraction II (160 μg) was added to the ubiquitination reactions shown in lanes 5 and 8, and Fraction I (160 μg) was added to the reactions in lanes 6 and 9.

Figure 3B is an autoradiogram showing the ubiquitination of bulk cellular proteins in HeLa extract. Lane 1 shows the ubiquitination in the absence of ATP, and lane 2 shows the ubiquitination in the presence of ATP, but without candidate modulating agent. In lanes 3-6, candidate modulating agents were added: 40μM doubly phosphorylated IκBα peptide (pp19 (SEQ ID NO:8), lane 3); 400μM c-Fos phosphopeptide (ppFos (SEQ ID NO:10), lane 4); 400μM serine 32, 36 to alanine substituted IκBα peptide (pp21S/A (SEQ ID NO:11), lane 5); and 40μM doubly phosphorylated IκBα peptide (pp21 (SEQ ID NO:9), lane 6).

Figures 4A-4F are micrographs showing the effect of candidate modulating agents on nuclear NF-κB translocation. In Figures 4A-C, pp21 (Figures 4A and 4B) or ppFos (Figure 4C) was microinjected into the cytoplasm of HeLa cells. Cells were then activated immediately with TNFα and immunostained with anti-p65 antibodies. In Figures 4D-F, pp21 (Figure 4D) or ppFos (Figure 4F) was injected into the cytoplasm of human vascular endothelial cells (HUVEC). Cells were then activated immediately with TNFα and immunostained with anti-E-selectin antibodies. Figure 4E is a phase contrast photograph of Figure 4D. In each micrograph, the injected cells are marked by large arrows. A non-injected, E-selectin negative cell is marked by a small arrow in Figures 4D and 4E.

Figures 4G and 4H are graphs presenting a summary of the microinjection experiments shown in Figures 4A - 4F. In Figure 4G, the percent of HeLa cells displaying nuclear p65 staining is shown. 90 and 42 cells were microinjected with pp21 and ppFos, respectively. Figure 4H shows the percent of HUVEC displaying E-selectin staining. 160 and 36 cells were microinjected with pp21 and ppFos, respectively. For each graph, column 1 shows the level in the absence of an IκB E3 recognition motif or other peptide and TNFα activation. Columns 2-4 show the

level following TNF α activation in the absence of peptide (column 2) or in the presence of pp21 (column 3) or ppFos (column 4).

Figure 5 is an autoradiogram depicting the results of a Western blot analysis showing the immunoprecipitation of pIkB α -associated ubiquitin-ligase activity from TNF α -activated cells. The pIkB α /NF- κ B complex was immunoprecipitated from proteasome-inhibited, TNF α -stimulated or non-stimulated HeLa cells and subjected to *in vitro* ubiquitination upon addition of ubiquitin, ATP- γ S and the following components: lane 1, UBC5C; lane 2, UBC5C and E1; lane 3, none; lanes 4-6, UBC5C and E1 as indicated; lane 7, UBC5C, E1 and pIkB α -peptide; lane 8, UBC5C, E1 and serine-substituted IkB α peptide; lane 9, a sample of TNF α -stimulated HeLa lysate. Cell-stimulation is indicated in the TNF α row. Monomeric and ubiquitin-conjugated IkB α are marked at the left, bottom and top of the figure.

Figure 6 is an autoradiogram illustrating the association of the ubiquitin-ligase with the IkB α /NF- κ B complex, following IKK-phosphorylation of IkB α at the DSG LDS (SEQ ID NOs:8 and 19) site. 35 S-labeled IkB α /NF- κ B complex immunopurified from non-activated cells was phosphorylated by IKK-2EE (where marked by + at the top), incubated with non-activated HeLa lysate as an E3 source, washed and subjected to *in vitro* ubiquitination in the presence of ATP γ S, ubiquitin, E1, UBC5C (except where an excluded component is indicated by Abst Ub-Enz). Lanes 2-7 show phosphorylation by IKK; lanes 1 and 3-7 show the effect of incubation with HeLa lysate; in lane 4, a pIkB α peptide was added during the incubation with HeLa lysate; in lane 5, serine-substituted IkB α peptide was added during HeLa incubation; in lane 6, E1 was omitted from the ubiquitination stage; and in lane 7, UBC5C was omitted during ubiquitination.

Figures 7A and 7B illustrate the identification of IkB α -binding proteins associated with ubiquitin-ligase activity. Figure 7A is a photograph showing Colloidal Blue staining of SDS-polyacrylamide gel samples of immunopurified fractions containing IkB α /NF- κ B and associated proteins. IkB α /NF- κ B complex was phosphorylated by IKK-2EE (lanes 2, 3) or mock-phosphorylated and used to adsorb the ubiquitin-ligase from HeLa lysate (lanes 1, 2). Molecular-size markers (kD) are indicated on the right. Proteins identified by mass-spectrometry analysis are indicated on the left. Gel-sites corresponding to the bands associated with the ubiquitin-ligase activity (p54 and p58) are marked on the left by brackets. Figure 7B is an autoradiogram of proteins adsorbed onto pIkB α /NF- κ B from 35 S-labeled HeLa cells. Radiolabeled HeLa lysate was incubated with IKK-phosphorylated antibody-immobilized IkB α /NF- κ B complex. The immune-complexes were then washed, eluted

and analyzed by SDS-PAGE and autoradiography. Lane 1 shows non-phosphorylated I κ B α /NF- κ B complex incubated with HeLa lysate; lanes 2-4 show phosphorylated I κ B α /NF- κ B-complex incubated with HeLa lysate in the absence (lane 2) or presence of pI κ B α -peptide (lane 3) or serine-substituted I κ B α -peptide (lane 4). Indicated on the left are molecular size markers (κ D), Rel A and I κ B α bands; indicated in the right are the four pI κ B α -associated bands, three of which were displaced by the pI κ B α peptide (arrows).

Figures 8A-8D show the results of a mass-spectrum analysis of ubiquitin-ligase associated p54. Figure 8A shows a nanoelectrospray mass spectrum of the unseparated tryptic peptide mixture from the 54 κ D gel band excised from a ligase-positive lane (equivalent to lane 2 in Figure 7B). Peaks marked by arrows were fragmented and identified as peptides derived from β -TrCP. The bar indicates the region enlarged in C. Figures 8B and 8C present a comparison of the nanoelectrospray spectra of the 54 κ D band associated with (C) and without (B) ubiquitin-ligase activity. The peptide at m/z 714.38 was selected for sequencing. Figure 8D is a fragmentation spectrum of the peptide identified in Figure 8C. A sequence tag was assembled from a series of doubly charged fragment ions and searched in the *nrdh* data-base for a matching pattern. Fragment masses calculated for the retrieved β -TrCP sequence AAVNVVDFDDKYIVSASGDR (SEQ ID NO:20) were compared with the complete fragmentation spectrum to confirm the match. Peaks matching expected fragment ions are marked by circles.

Figures 9A and 9B present the sequence of a polynucleotide encoding a human E3 ubiquitin ligase (SEQ ID NO:15).

Figure 10 presents a human E3 ubiquitin ligase protein sequence (SEQ ID NO:16).

Figures 11A-11C are Western blots illustrating binding and ubiquitination specificity of E3 ubiquitin ligase family members. Within these figures, m β -TrCP indicates mouse β -TrCP, h β -TrCP indicates human β -TrCP, $\Delta\beta$ -TrCP indicates human β -TrCP with a deletion of the F box region and Slimb indicates the *Drosophila* Slimb protein. Figure 11A illustrates selective binding to pI κ B α . Proteins were immunoprecipitated through a FLAG epitope from transfected 293T cells, incubated with immunopurified I κ B α /NF- κ B complex, which had been treated (-/+ IKK) as indicated and the bound material was analyzed by Western blotting with the indicated antibodies. The top panel shows specific pI κ B α binding; the middle panel shows 10% of the substrate flow-through; the bottom panel is a blot of the immunoprecipitated proteins; and molecular size markers (κ D) are indicated on the left.

Figure 11B shows that β -TrCP- $\text{I}\kappa\text{B}\alpha$ binding is abrogated by a phosphopeptide representing the $\text{I}\kappa\text{B}\alpha$ degradation motif¹ (pp10), but not by a related non-phosphorylated peptide¹ (pS/A). Figure 11C illustrates *in vitro* ubiquitination of $\text{I}\kappa\text{B}\alpha$ by the E3 family member proteins. Immunopurified FLAG-tagged proteins were
5 incubated with ^{35}S -labeled $\text{I}\kappa\text{B}\alpha$ /NF- κB complexes, treated (-/+ IKK) as indicated and subject to ubiquitination in the presence of ATP γ S, ubiquitin, E1 and UBC5C. The $\text{I}\kappa\text{B}\alpha$ substrate (composed of full-length and two degradation products), $\text{I}\kappa\text{B}\alpha$ -polyubiquitin conjugates and molecular size markers are indicated on the left.

Figures 12A and 12B illustrate inhibition of $\text{I}\kappa\text{B}\alpha$ degradation and NF-
10 κB activation by overexpression of $\Delta\beta$ -TrCP, a dominant negative molecule. Figure 12A is a graph depicting the results of a κB -dependent luciferase assay in P/I-stimulated Jurkat cells transfected with κB -Luc reporter plasmid and the indicated expression vectors (*i.e.*, from left to right, vector alone, vector encoding human β -TrCP, vector encoding human β -TrCP with a deletion of the F box region and vector
15 encoding *Drosophila* Slimb protein). NF- κB activity is shown as relative (fold) luciferase activity, the non-stimulated empty FLAG vector being the reference (single-fold). Figure 12B depicts the results of western blot analysis of $\text{I}\kappa\text{B}\alpha$ of phorbol-ester and Ca^{++} ionophore [P/I]-stimulated and non-stimulated Jurkat cells transfected with an empty FLAG vector or $\Delta\beta$ -TrCP. The post-stimulation interval (min) is indicated.

20 DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods useful for modulating the activation of nuclear factor κB (NF- κB) and for treating diseases associated with such activation. In particular, the invention is directed to agents that modulate ubiquitination of phosphorylated $\text{I}\kappa\text{B}$ (*i.e.*,
25 $\text{I}\kappa\text{B}\alpha$ and/or $\text{I}\kappa\text{B}\beta$). Such ubiquitination results in the release and activation of NF- κB .

The present invention is based, in part, on the identification and characterization of a human E3 ubiquitin ligase that recognizes phosphorylated and NF- κB -associated $\text{I}\kappa\text{B}$. Polypeptides comprising this E3 ubiquitin ligase, as well as portions and other variants thereof, may be used to modulate NF- κB activity *in vitro* or
30 in a patient. Such polypeptides may also be used, for example, to identify agents (such as small molecules) that may be used to modulate NF- κB activity, and to treat disorders associated with abnormal NF- κB activation.

HUMAN E3 UBIQUITIN LIGASE POLYPEPTIDES AND POLYNUCLEOTIDES

It has been found, within the context of the present invention, that a human E3 ubiquitin ligase that migrates as a 54 kD protein binds to, and enhances ubiquitination of, phosphorylated I κ B α (phosphorylated I κ B α is also designated herein as pI κ B α). The sequence of a polynucleotide encoding a human E3 ubiquitin ligase is provided in Figure 9 and SEQ ID NO:15; and a full length human E3 ubiquitin ligase protein sequence is provided in Figure 10 and SEQ ID NO:16. Human E3 ubiquitin ligase has also been found, within the context of the present invention, to be a member of a family of F-box/WD proteins that includes β -TrCP (Margottin et al., *Mol. Cell* 1:565-574, 1998) and the Drosophila Slimb protein (see Jiang and Struhl, *Nature* 391:493-496, 1998). As described in greater detail below, other members of this family share certain properties of E3, and such proteins and variants thereof may be used within certain methods provided herein for E3.

Human E3 ubiquitin ligase polypeptides encompassed by the present invention include native human E3 ubiquitin ligase (also referred to herein as "E3"), as well as portions and other variants thereof. Variants of E3 may differ in sequence from native E3 due to one or more amino acid substitutions, deletions, additions and/or insertions, as described herein, provided that the variant binds to and enhances ubiquitination of an I κ B polypeptide as described herein. Preferably, a variant of E3 contains amino acid substitutions at no more than 20%, preferably no more than 15% and more preferably no more than 10%, of the residues recited in SEQ ID NO:16. Variants further include truncated polypeptides and polypeptides containing additional amino acid sequences that have minimal influence on the activity of the polypeptide. A human E3 ubiquitin ligase polypeptide may be of any length, provided that it retains the recited properties. In other words, such a polypeptide may be an oligopeptide (*i.e.*, consisting of a relatively small number of amino acid residues, such as 8-10 residues, joined by peptide bonds), a full length protein (or variant thereof) or a polypeptide of intermediate size (*e.g.*, 20, 50, 200 or 400 amino acid residues).

Certain variants contain conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. Amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and

amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydrophobic nature of the polypeptide.

As noted above, certain E3 polypeptides may contain additional amino acid sequences at the amino and/or carboxy termini. For example, an E3 sequence may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. A polypeptide may also, or alternatively, be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

The ability of an E3 polypeptide to bind to phosphorylated I κ B may be readily determined using any binding assay known to those of ordinary skill in the art. For example, pI κ B α /NF- κ B complexes may be incubated with immobilized E3 polypeptide, and the level of I κ B α binding evaluated using anti-I κ B α antibodies (in, for example, a Western blot). Within such assays, an E3 polypeptide should bind detectably to the I κ B α ; preferably the E3 polypeptide binds at a level that is not substantially diminished relative to the native human E3. In other words, the ability of a variant to bind detectably to phosphorylated and complexed I κ B α may be enhanced or unchanged, relative to the native polypeptide, or may be diminished by less than 50%, and preferably less than 20%, relative to the native polypeptide. It will be apparent that other suitable substrates may be substituted for pI κ B α /NF- κ B complexes within such assays.

The ability of an E3 polypeptide to enhance ubiquitination of phosphorylated I κ B may be assessed by incubating the polypeptide with I κ B α /NF- κ B complex, along with ATP γ S, ubiquitin E1 and ubiquitin E2, and detecting the slow-moving I κ B α -ubiquitin conjugates by Western blot using I κ B α -specific antibodies, as described herein. In general, an E3 polypeptide should result in a detectable level of ubiquitination within such an assay; preferably the level of ubiquitination is not

substantially diminished relative to the level of ubiquitination generated by a similar amount of native human E3.

Also encompassed by the present invention are polypeptides comprising a portion or other variant of E3 that retains the ability to bind to phosphorylated I κ B, but does not retain the ability to enhance ubiquitination of I κ B. Such polypeptides may be readily identified using the binding assays and ubiquitination assays provided herein, and may generally be used to inhibit ubiquitination of I κ B. Such polypeptides include those from which the F-box region (*i.e.*, a region of the protein that interacts with one or more components of the ubiquitin cascade) has been deleted. F box regions may generally be identified functionally (*i.e.*, deletion of an F-box region results in a protein that fails to recruit appropriate components of the ubiquitin machinery) and based on the presence of an F-box region consensus sequence (*see* Patton et al., Trends in Genet. 14:236-243, 1998). Certain such polypeptides contain a deletion of amino acids 122-168 of SEQ ID NO:16. Within certain embodiments, portions of E3 may comprise 10 to 374 consecutive amino acid residues, preferably 50 to 250, consecutive amino acid residues of the sequence recited in SEQ ID NO:16.

The present invention further provides polynucleotides that encode an E3 polypeptide as provided herein. Any polynucleotide that encodes such a polypeptide, or a portion or variant thereof as described herein, is encompassed by the present invention. Such polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

Native DNA sequences encoding a human E3, or portion thereof, may be isolated using any of a variety of hybridization or amplification techniques, which are well known to those of ordinary skill in the art. Within such techniques, probes or primers may be designed based on the E3 sequence provided herein, and may be purchased or synthesized. Libraries from any suitable tissue may be screened. An amplified portion or partial cDNA molecule may then be used to isolate a full length gene from a genomic DNA library or from a cDNA library, using well known techniques. Alternatively, a full length gene can be constructed from multiple PCR fragments. Partial and full length polynucleotides comprising such sequences, other portions of full length polynucleotides, and sequences complementary to all or a portion of such full length molecules, are specifically encompassed by the present

invention. In addition, homologues from other species are specifically contemplated, and may generally be prepared as described herein.

Polynucleotide variants of the recited sequences may differ from a native E3 polynucleotide in one or more substitutions, deletions, insertions and/or additions. Preferred variants contain nucleotide substitutions, deletions, insertions and/or additions at no more than 20%, preferably at no more than 10%, of the nucleotide positions. Certain variants are substantially homologous to a native gene, or a portion or complement thereof. Such polynucleotide variants are capable of hybridizing under moderately stringent conditions to a naturally occurring DNA sequence encoding an E3 protein (or a complementary sequence). Suitable moderately stringent conditions include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5 X SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS). Such hybridizing DNA sequences are also within the scope of this invention.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention.

As noted above, the present invention further provides antisense polynucleotides and portions of any of the above sequences. Such polynucleotides may generally be prepared by any method known in the art including, for example, solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* or *in vivo* transcription of DNA sequences that are incorporated into a vector downstream of a suitable RNA polymerase promoter (such as T3, T7 or SP6). Certain portions of a polynucleotide may be used to prepare an encoded polypeptide, as described herein. In addition, or alternatively, a portion may function as a probe (*e.g.*, to detect E3 expression in a sample), and may be labeled by a variety of reporter groups, such as radionuclides, fluorescent dyes and enzymes. Such portions are preferably at least 10 nucleotides in length, and more preferably at least 20 nucleotides in length. Within certain preferred embodiments, a portion for use as a probe comprises a sequence that is unique to an E3 gene. A portion of a sequence complementary to a coding sequence (*i.e.*, an antisense polynucleotide) may also be used as a probe or to modulate gene expression. DNA constructs that can be

transcribed into antisense RNA may also be introduced into cells or tissues to facilitate the production of antisense RNA.

Any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of flanking
5 sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

Polynucleotides as described herein may be joined to a variety of other
10 nucleotide sequences using established recombinant DNA techniques. For example, a polynucleotide may be cloned into any of a variety of cloning vectors, including plasmids, phagemids, lambda phage derivatives and cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors. In general, a vector will contain an origin of replication functional
15 in at least one organism, convenient restriction endonuclease sites and one or more selectable markers. Additional initial, terminal and/or intervening DNA sequences that, for example, facilitate construction of readily expressed vectors may also be present. Suitable vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art. Other elements that may be present in a
20 vector will depend upon the desired use, and will be apparent to those of ordinary skill in the art.

Vectors as described herein may generally be transfected into a suitable host cell, such as a mammalian cell, by methods well-known in the art. Such methods include calcium phosphate precipitation, electroporation and microinjection.

25 E3 polypeptides may generally be prepared using standard automated synthesis techniques or by expression of recombinant DNA encoding the desired polypeptide. In general, peptides may be prepared synthetically using standard techniques, incorporating amino acids and/or amino acid analogs. During synthesis, active groups of amino acids and/or amino acid analogs may be protected as necessary
30 using, for example, a t-butyldicarbonate (t-BOC) group or a fluorenylmethoxy carbonyl (FMOC) group. Amino acids and amino acid analogs may be purchased commercially (e.g., Sigma Chemical Co.; Advanced Chemtec) or synthesized using methods known in the art. Peptides may be synthesized using a solid phase method, in which the peptides are attached to a resin such as 4-methylbenzhydrylamine (MBHA), 4-
35 (oxymethyl)-phenylacetamido methyl- and 4-(hydroxymethyl)phenoxy methyl-copoly(styrene-1% divinylbenzene) (Wang resin), all of which are commercially

available, or to p-nitrobenzophenone oxime polymer (oxime resin) which can be synthesized as described by De Grado and Kaiser, *J. Org. Chem.* 47:3258, 1982. Those skilled in the art will realize that the choice of amino acids and/or amino acid analogs will depend, in part, on the specific physical, chemical or biological characteristics desired. Such characteristics are determined, in part, by the method of administration and the target location within a patient.

Selective modification of the reactive groups in a peptide can also impart desirable characteristics. Peptides can be manipulated while still attached to the resin to obtain N-terminal modified compounds such as an acetylated peptide or can be removed from the resin using hydrogen fluoride or an equivalent cleaving agent and then modified. Compounds synthesized containing the C-terminal carboxy group (Wang resin) can be modified after cleavage from the resin or, in some cases, prior to solution phase synthesis. Methods for modifying the N-terminus or C-terminus of a peptide are well known in the art and include, for example, methods for acetylation of the N-terminus or amidation of the C-terminus. Similarly, methods for modifying side chains of the amino acids or amino acid analogs are well known to those skilled in the art of peptide synthesis. The choice of modifications made to reactive groups present on the peptide will be determined by the desired characteristics.

An E3 polypeptide may also be a cyclic peptide. A cyclic peptide can be obtained by inducing the formation of a covalent bond between, for example, the amino group at the N-terminus of the peptide and the carboxyl group at the C-terminus. Alternatively, a cyclic peptide can be obtained by forming a covalent bond between a terminal reactive group and a reactive amino acid side chain or between two reactive side chains. It will be apparent to those of skill in the art that a cyclic peptide is selected based on the desired properties. For example, a cyclic peptide may provide increased stability, increased solubility, decreased immunogenicity or decreased clearance *in vivo*.

A newly synthesized peptide can be purified using a method such as reverse phase high performance liquid chromatography (RP-HPLC) or other methods of separation based on size or charge. Furthermore, a purified peptide can be characterized using these and other well known methods such as amino acid analysis and mass spectrometry.

Alternatively, polypeptides may generally be prepared from nucleic acid encoding the desired polypeptide using well known techniques. To prepare an endogenous protein, an isolated cDNA may be used. To prepare a variant polypeptide, standard mutagenesis techniques, such as oligonucleotide-directed site-specific

mutagenesis may be used, and sections of the DNA sequence may be removed to permit preparation of truncated polypeptides.

In general, any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides of this invention. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA sequence that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, baculovirus-infected insect cells and animal cells. Following expression, supernatants from host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. One or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.

In general, polypeptides and polynucleotides as described herein are isolated. An "isolated" polypeptide or polynucleotide is one that is removed from its original environment. For example, a naturally-occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, polypeptides provided herein are isolated to a purity of at least 80% by weight, more preferably to a purity of at least 95% by weight, and most preferably to a purity of at least 99% by weight. In general, such purification may be achieved using, for example, the standard techniques of ammonium sulfate fractionation, SDS-PAGE electrophoresis, and affinity chromatography. A polynucleotide is considered to be isolated if, for example, it is cloned into a vector that is not a part of the natural environment.

ANTIBODIES

The present invention further provides antibodies, and antigen-binding fragments thereof, that specifically bind to an E3 polypeptide. As used herein, an antibody, or antigen-binding fragment, is said to "specifically bind" to a polypeptide if it reacts at a detectable level (within, for example, an ELISA) with the polypeptide, and does not react detectably with unrelated proteins. Antibodies may be polyclonal or monoclonal. Preferred antibodies are those antibodies that inhibit or block E3 activity and within a ubiquitination assay as described herein. Other preferred antibodies (which may be used, for example, in immunokinase assays) are those that immunoprecipitate active E3, as determined using any standard assay, such as an assay provided herein.

Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art (*see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988). In one such technique, an immunogen comprising the polypeptide is initially injected into a suitable animal (*e.g., mice, rats,*
5 *rabbits, sheep and goats*), preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

10 Monoclonal antibodies may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (*i.e., reactivity with the polypeptide of interest*). Such cell lines may be produced, for example, from spleen
15 cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells,
20 but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

25 Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the
30 antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction.

Within certain embodiments, the use of antigen-binding fragments of antibodies may be preferred. Such fragments include Fab fragments, which may be prepared using standard techniques. Briefly, immunoglobulins may be purified from
35 rabbit serum by affinity chromatography on Protein A bead columns (Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988) and digested

by papain to yield Fab and Fc fragments. The Fab and Fc fragments may be separated by, for example, affinity chromatography on protein A bead columns.

UBIQUITINATION ASSAYS

5 As noted above, the ability of an E3 polypeptide to modulate ubiquitination of phosphorylated I κ B may be assessed by incubating the polypeptide with I κ B α /NF- κ B complex (or any other suitable substrate), along with ATP γ S, ubiquitin E1 and ubiquitin E2, and detecting I κ B α -ubiquitin conjugates by, for example, Western blot using I κ B α -specific antibodies. I κ B polypeptides for use in a ubiquitination assay as described herein may be native human I κ B α (SEQ ID NO:1) or I κ B β (SEQ ID NO:3), or may be a variant of a native protein. Polypeptide variants of I κ B are generally modified such that the ability of the variant to be phosphorylated and ubiquitinated within a ubiquitination assay as described herein is not substantially diminished. An I κ B polypeptide may be labeled. For example, 35 S may be incorporated into a I κ B polypeptide by *in vitro* translation of the polypeptide in the presence of 35 S-methionine, using standard techniques.

 An I κ B polypeptide may generally be prepared from DNA encoding the polypeptide by expression of the DNA in cultured host cells or by translation using an *in vitro* system such as wheat germ extract. If host cells are employed, such cells are preferably are bacteria, yeast, baculovirus-infected insect cells or mammalian cells. The recombinant DNA may be cloned into any expression vector suitable for use within the host cell, using techniques well known to those of ordinary skill in the art. *In vitro* translation of polypeptide may generally be performed according to the manufacturer's instructions.

25 Expressed I κ B polypeptides may be used without purification following *in vitro* translation. Alternatively, a polypeptide may be isolated in substantially pure form. An I κ B polypeptide may be isolated to a purity of at least 80% by weight, preferably to a purity of at least 95% by weight, and more preferably to a purity of at least 99% by weight. In general, such purification may be achieved using, for example, the representative purification method described herein or the standard techniques of ammonium sulfate fractionation, SDS-PAGE electrophoresis, and affinity chromatography.

 Certain ubiquitination assays may employ a cellular E3 to characterize modulators of E3 activity. Within such assays, cellular extracts from stimulated or non-stimulated Jurkat, HeLa, THP-1 or endothelial cells may be incubated *in vitro* with an I κ B polypeptide in the presence of ATP and the phosphatase inhibitor okadaic acid.

Cellular extracts may generally be prepared according to the method of Alkalay et al., *Proc. Natl. Acad. Sci. USA* 92:10599, 1995. The incubation is performed under conditions sufficient to result in phosphorylation of the I κ B polypeptide (at serines 32 and 36 for I κ B α and variants thereof) and association of the phosphorylated polypeptide (pI κ B) with the cellular-derived NF- κ B complex. For example, I κ B polypeptide may be incubated with HeLa or Jurkat cell extract, ATP and okadaic acid. Incubation for 90 minutes at 30°C is generally sufficient to allow phosphorylation of the I κ B polypeptide. Following this incubation, the pI κ B/NF- κ B complex may be immunopurified with, for example, anti-p65 antibodies and subjected to *in vitro* ubiquitination in a cell free system, as described by Alkalay et al., *Proc. Natl. Acad. Sci. USA* 92:10599, 1995. The level of ubiquitination may then be evaluated using the well known techniques of SDS-PAGE, followed by autoradiography.

Under these conditions, a wild type ³⁵S-pI κ B α polypeptide generates multiply ubiquitinated species in the presence of ATP γ S (see Figure 1A, lane 4). Neither ³⁵S-labeled S32/36A mutant of I κ B α (lane 1), nor the non-phosphorylated wild type ³⁵S-I κ B α (lane 2) are ubiquitinated. However, free forms of either mutant or wild type I κ B α are readily conjugated (Figure 1B). Similarly, a free (but not a complex-associated) lysine 21, 22 mutant of I κ B α can be ubiquitinated *in vitro*. Thus, unlike ubiquitination assays performed using free I κ B polypeptides, the ubiquitination assay provided herein targets only I κ B polypeptides that are complex-associated and appropriately phosphorylated.

A ubiquitination assay as described above may be used to identify agents that modulate ubiquitination of I κ B. Modulating agents may include antibodies (*e.g.*, monoclonal), peptides, small molecules (*e.g.*, from a combinatorial library) and other drugs that stimulate or, preferably, inhibit ubiquitination of an I κ B α and/or I κ B β polypeptide. In general, such agents may be identified by including a candidate modulating agent in the ubiquitination reaction, which may otherwise be performed as described above, and evaluating the effect of the agent on the level of ubiquitination. A suitable concentration of candidate agent for use in such an assay generally ranges from about 0.1 μ M to about 1 mM. For peptide candidate agents, a peptidase inhibitor such as Bestatin (40 μ g/mL) may also be added, and the amount of peptide preferably ranges from about 10 μ M to about 1 mM. A candidate agent that results in a statistically significant effect on the level of ubiquitination is a modulating agent encompassed by the present invention.

Agents may be further evaluated by microinjection of the agent (*e.g.*, about 5 mg/mL of a peptide agent) into a suitable cell (*e.g.*, HeLa cell or primary

human vascular endothelial cell). Following microinjection, cells may be stimulated (e.g., with $\text{TNF}\alpha$) and incubated to allow NF- κ B activation. In HeLa cells, $\text{TNF}\alpha$ induces rapid nuclear translocation of NF- κ B into the nucleus, which may be detected by staining with p65-specific antibodies. Modulating agents induce a statistically significant decrease in NF- κ B translocation, and may reduce such translocation to undetectable levels.

Primary human vascular endothelial cells (HUVEC) respond to $\text{TNF}\alpha$ stimulation by surface expression of NF- κ B regulated adhesion proteins such as ICAM-1, V-CAM-1 and E-selectin (Read et al.; *Immunity* 2:493,1995; Chen et al., *J. Immunol* 155:3538, 1995). E-selectin expression is particularly NF- κ B dependent and is the major inducible endothelial adhesion molecule for initial neutrophil attachment and rolling on activated endothelium. Stimulated cells may be fixed and stained to detect expression of one or more NF- κ B regulated adhesion proteins. Microinjection of a polypeptide or other modulating agent results in a statistically significant inhibition of such expression, but does not affect the expression of NF- κ B independent adhesion proteins, such as ICAM2.

THERAPEUTIC APPLICATIONS

As noted above, certain E3 polypeptides, polynucleotides, antibodies and other agents as described herein may generally be used as modulating agents to specifically inhibit or enhance cellular NF- κ B functions. Modulating agents may also be used to modulate ubiquitination of $\text{I}\kappa\text{B}\alpha$ and/or $\text{I}\kappa\text{B}\beta$ in a patient, thereby modulating NF- κ B cellular function *in vivo*. As used herein, a "patient" may be any mammal, including a human, and may be afflicted with a disease associated with NF- κ B activation, or may be free of detectable disease. Accordingly, the treatment may be of an existing disease or may be prophylactic. Diseases associated with NF- κ B activation include, but are not limited to, inflammatory diseases, autoimmune diseases, cancer and viral infection.

Treatment refers to administration of a modulating agent as described herein. For administration to a patient, one or more such compounds are generally formulated as a pharmaceutical composition. A pharmaceutical composition may be a sterile aqueous or non-aqueous solution, suspension or emulsion, which additionally comprises a physiologically acceptable carrier (*i.e.*, a non-toxic material that does not interfere with the activity of the active ingredient). Any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of the present invention. Representative carriers include physiological saline solutions,

gelatin, water, alcohols, natural or synthetic oils, saccharide solutions, glycols, injectable organic esters such as ethyl oleate or a combination of such materials. Optionally, a pharmaceutical composition may additionally contain preservatives and/or other additives such as, for example, antimicrobial agents, anti-oxidants, 5 chelating agents and/or inert gases, and/or other active ingredients.

Alternatively, a pharmaceutical composition may comprise a polynucleotide encoding a modulating agent (such that the modulating agent is generated *in situ*) in combination with a physiologically acceptable carrier. In such pharmaceutical compositions, the polynucleotide may be present within any of a variety 10 of delivery systems known to those of ordinary skill in the art, including nucleic acid, bacterial and viral expression systems, as well as colloidal dispersion systems, including liposomes. Appropriate nucleic acid expression systems contain the necessary polynucleotide sequences for expression in the patient (such as a suitable promoter and terminating signal). DNA may also be "naked," as described, for 15 example, in Ulmer et al., *Science* 259:1745-1749, 1993.

Various viral vectors that can be used to introduce a nucleic acid sequence into the targeted patient's cells include, but are not limited to, vaccinia or other pox virus, herpes virus, retrovirus, or adenovirus. Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. Preferably, 20 the retroviral vector is a derivative of a murine or avian retrovirus including, but not limited to, Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A retroviral vector may additionally transfer or incorporate a gene for a selectable marker (to aid in the identification or selection of transduced cells) and/or a gene that 25 encodes the ligand for a receptor on a specific target cell (to render the vector target specific). For example, retroviral vectors can be made target specific by inserting a nucleotide sequence encoding a sugar, a glycolipid, or a protein. Targeting may also be accomplished using an antibody, by methods known to those of ordinary skill in the art.

Viral vectors are typically non-pathogenic (defective), replication 30 competent viruses, which require assistance in order to produce infectious vector particles. This assistance can be provided, for example, by using helper cell lines that contain plasmids that encode all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR, but that are missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA transcript for 35 encapsulation. Such helper cell lines include (but are not limited to) Ψ2, PA317 and PA12. A retroviral vector introduced into such cells can be packaged and vector virion

produced. The vector virions produced by this method can then be used to infect a tissue cell line, such as NIH 3T3 cells, to produce large quantities of chimeric retroviral virions.

Another targeted delivery system for polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (*i.e.*, an artificial membrane vesicle). It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0 μm can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.* 6:77, 1981). In addition to mammalian cells, liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells. In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannino, et al., *Biotechniques* 6:882, 1988).

The targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity and may be, for example, organ-specific, cell-specific, and/or organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticuloendothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.

Routes and frequency of administration, as well doses, will vary from patient to patient. In general, the pharmaceutical compositions may be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity or transdermally. Between 1 and 6 doses may be administered daily. A suitable dose is an amount that is sufficient to show improvement in the symptoms of a patient afflicted

with a disease associated with NF- κ B activation. Such improvement may be detected by monitoring inflammatory responses (*e.g.*, edema, transplant rejection, hypersensitivity) or through an improvement in clinical symptoms associated with the disease. In general, the amount of modulating agent present in a dose, or produced *in situ* by DNA present in a dose, ranges from about 1 μ g to about 100 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 10 mL to about 500 mL for 10-60 kg animal.

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLES

Example 1Identification of an I κ B E3 Recognition Motif Using Ubiquitination Assay

5

This Example illustrates a representative ubiquitination assay, and the use of such an assay to evaluate peptides for the ability to inhibit I κ B ubiquitination.

A. In vitro Ubiquitination Assay

HA-tagged I κ B α or HA-tagged I κ B β cDNAs (Haskill et al., *Cell* 10 65:1281-1289, 1991) were translated *in vitro* in wheat germ extract in the presence of ³⁵S-methionine according to the manufacturer's instructions (Promega, Madison, WI). To phosphorylate I κ B α or I κ B β , 1 μ l of the extract containing the labeled protein was incubated for 90 minutes at 30°C in a reaction mixture having a final volume of 30 μ l: 100 μ g HeLa or Jurkat cell extract (prepared as described by Alkalay et al., *Proc. Natl.* 15 *Acad. Sci. USA* 92:10599, 1995), 2mM ATP and 1 μ M okadaic acid. During this incubation, the labeled I κ B polypeptide was phosphorylated at serines 32 and 36, and associated with the endogenous NF- κ B complex (data not shown).

Following incubation, 1 μ l of anti-p65 serum was added, and the NF- κ B immune complex was immobilized to Protein A-Sepharose[®] and subjected to *in vitro* 20 ubiquitination in HeLa cell extract as described by Alkalay et al.. Ubiquitinated proteins were separated by SDS-PAGE and visualized by autoradiography.

As shown in Figure 1A, only wild type ³⁵S-pI κ B α generated multiply ubiquitinated species (lane 4). Neither ³⁵S-labeled S32/36A mutant of I κ B α (lane 1) nor the non-phosphorylated wild type ³⁵S-I κ B α (lane 2) were ubiquitinated, and no 25 ubiquitination of pI κ B α was seen in the absence of ATP (lane 3).

The physiological relevance of this assay was further documented by comparison of *in vitro* ubiquitination of free ³⁵S-I κ B to that of a complex-associated, phosphorylated substrate. Whereas a complex-associated S32/36A mutant was not subject to ubiquitin conjugation in accordance with its *in vivo* fate, free forms of either 30 mutant or wild type I κ B α were readily conjugated (Figure 1B). Similarly, only free, but not a complex-associated lysine 21, 22 mutant of I κ B α could be ubiquitinated *in vitro* (data not shown). Thus, while the free I κ B α is recognized by the ubiquitin system in a non-discriminatory manner, the complex-associated inhibitor is masked unless it is appropriately phosphorylated.

B. Identification of the I κ B α -Ubiquitin Ligase Recognition Motif

To identify the I κ B α -ubiquitin ligase recognition motif, various peptides were added at varying concentrations to the reaction mixtures in the presence of the peptidase inhibitor Bestatin (40 μ g/ml). The peptides spanned the N-terminal signaling domain of the protein, and were phosphorylated at one or both serine residues (32 and 36), or were unmodified or serine-substituted. These peptides were included in the ubiquitination reaction at different concentrations and tested for inhibition of pI κ B α specific ubiquitination. When conjugation of free I κ B α was monitored, the translated protein was added directly to the conjugation reaction mixture.

Only peptides that were phosphorylated at both serine 32 and 36 (pI κ B α peptides) effectively inhibited pI κ B α ubiquitination (Figure 1A, lanes 7, 11-14). A c-Fos phosphopeptide (ppFos, lane 5), a serine 32, 36 to alanine substituted I κ B α peptide (p21 S/A, lane 6) and a non-phosphorylated peptide (p21, lane 8) had no detectable effect on the ubiquitination of pI κ B at a concentration of 400 μ M. The IC₅₀ of the phosphorylated I κ B α peptides were calculated and representative inhibitory concentrations are shown in Figure 1A. Doubly phosphorylated I κ B α peptides inhibited the pI κ B conjugation reaction (lanes 7, 11-14) at an IC₅₀ of 5 μ M. The sequences of these peptides are provided in Table I, above, and in SEQ ID NOs:5-9. In contrast, singly phosphorylated peptides (lanes 9, 10) inhibited the pI κ B α conjugation at an IC₅₀ of 400 μ M. The minimal size peptide tested (pp7, lane 14), merely spanning the signaling phosphorylation site, was sufficient to effectively inhibit the ubiquitination, although at somewhat higher IC₅₀ (10 μ M). Thus, a peptide comprising residues 21 to 41 of SEQ ID NO:1 comprises a recognition domain for E3 ubiquitin ligase. Interestingly, lysine residues 21 and 22 are not essential for inhibition, implying that the ubiquitin-system recognition site is distinct from the actual conjugation site.

The specificity of the peptides was tested in two other ubiquitin-conjugation reactions: the conjugation of free wild type (Figure 1B lanes 1-3) or S32/36A mutant I κ B α (Figure 1B, lanes 4-6) and the ubiquitin conjugation to the bulk of cellular proteins in HeLa extract (detected by ¹²⁵I-labeled ubiquitin according to Alkalay et al., Figure 1C). Neither reaction was affected by the addition of an I κ B α -ubiquitin ligase recognition motif or a control peptide.

Peptides comprising an I κ B α -ubiquitin ligase recognition motif were found to abolish the ubiquitination of the pI κ B α related substrate pI κ B β (Figure 1D). Similar to the conjugation of pI κ B α , the specific conjugation of the I κ B β also required an associated NF- κ B complex (not shown) and prior phosphorylation at the I κ B α -homologous residues Ser 19 and 23. An I κ B β substrate prepared in the absence of

phosphatase inhibitors was not subject to ubiquitination (Figure 1D, lane 1). Peptides affected pIkB β ubiquitination at an IC₅₀ that was similar to that observed for pIkB α (Figure 1D, lanes 4-7). Hence, it appears that the same enzyme(s) target both IkBs for ubiquitin-dependent degradation.

5 The inhibitory pIkB α peptides were tested in a complementary ubiquitin-dependent *in vitro* degradation assay (Orian et al., *J. Biol. Chem.* 270:21707, 1995; Stancovski et al., *Mol. Cell. Biol.* 15:7106, 1995). Using this assay, only pIkB α derived from stimulated cells is degraded *in vitro* in a ubiquitin-dependent manner, whereas the non-phosphorylated IkB α from the same cell extract is not subject to
10 degradation. Incorporation of the conjugation-inhibitory phosphopeptides into the degradation assay resulted in stabilization of the pIkB α substrate (Figure 2, lanes 3, 4) whereas the non-phosphorylated peptide agent or a control phospho-Fos peptide had no effect on the specific pIkB α degradation (lanes 5, 6). Trimming the peptides at Lys 21/22 did not diminish the degradation inhibitory effect (lane 4), indicating that the
15 peptides do not abolish pIkB α degradation by exhausting the ubiquitin-proteasome system as conjugatable substrates.

Example 2

Identification of Ubiquitin System Component Involved in Substrate Recognition

20

This Example illustrates the identification of a specific E3 that is responsible for recognition of pIkB polypeptides.

pIkB α -ubiquitin conjugation and degradation requires a full complement of the ubiquitin system enzymes: E1, a specific E2 derived from the ubiquitin system
25 fraction I, E2F1 (Alkalay et al., *Proc. Natl. Acad. Sci. USA* 92:10599, 1995; Chen et al., *Cell* 84:853, 1996) and a Fraction II-component E3. To identify the ubiquitin system component involved in the substrate recognition, HeLa lysate was fractionated over IkB α phosphopeptide columns, and the flow-through fractions were assayed for pIkB α conjugation. Peptides were coupled to NHS-Sepharose[®] (Pharmacia) according
30 to the manufacturer's instructions at a concentration of 2 mg/ml. 100 μ g of HeLa extract were incubated with 2.5 μ l coupled resin in the presence of 0.1% NP40 and 3% ovalbumin for 1 hour at 4°C. The resin was discarded and the unbound material tested in the ubiquitination assay described above.

Whereas a flow-through fraction from a control phosphopeptide column
35 and an S32/36A peptide column retained full IkB α conjugation capacity (Figure 3A, lanes 2, 3) flow-through fractions from two different pIkB α peptides lost their IkB α

specific conjugation capacity (lanes 4, 7). The depleted conjugating activity could be complemented by reticulocyte Fraction II (lanes 5, 8) that contains all the known species of E3 enzymes (Ciechanover, *Cell* 79:13, 1994). Complementation could not be obtained by the addition of Fraction I or Fraction I and E1 (lanes 6 and 9, respectively), indicating that the peptide columns depleted an E3 rather than E2 or E1. Again, I κ B α lysine residues 21 and 22 were dispensable for retaining the E3 (compare Figure 3A, lane 7 to lane 4), emphasizing the distinction between the substrate recognition and conjugation site. The peptide column depletion was found to be specific for the I κ B E3, as all flow-through fractions maintained full activity in random HeLa protein conjugation (as detected by measuring the conjugation of 125 I ubiquitin, Figure 3B). This indicates that a specific E3 is responsible for recognition of the pI κ Bs at the identified motif.

Example 3

Effect of Representative Peptides on Cellular NF- κ B Activation

This Example illustrates the inhibition of cellular NF- κ B activation by microinjection of peptides comprising an I κ B α -ubiquitin ligase recognition motif.

HeLa cells were plated on a grid coverslips (Cellocate, Eppendorf) 18 hours before microinjection. Microinjection was performed with a 22 amino acid pI κ B α peptide (pp21; Table I and SEQ ID NO:9) or a control phospho-Fos peptide (SEQ ID NO:10) using a semi-automated apparatus (Eppendorf). Peptides were injected into the cell cytoplasm at a concentration of 5 mg/ml in 100 mM KCl, 5mM Na₂HPO₄ (pH 7.2), and immediately activated with TNF α (200 units/mL) for either 20 minutes (for NF- κ B translocation) or 3 hours (for E-selectin expression). Following activation, the cells were fixed and stained with p65 specific antibodies (Mercurio et al., *Genes & Dev.* 7:705, 1993; Santa Cruz) or monoclonal anti-E-selectin antibodies (R&D Systems).

In the absence of peptide, TNF α induces rapid nuclear translocation of NF- κ B into the nucleus, as shown by the p65 nuclear staining of 90% of the cells (*see* Figure 4G, column 2). The pp21 peptide abolished TNF α -stimulated NF- κ B activation in 50%-70% of the microinjected cells in several experiments (*see* representative fields in Figures 4A and 4B; and Figure 4G, column 3). In contrast, the control pp-Fos peptide had no effect on the rate of NF- κ B induced nuclear translocation, as compared to non-microinjected cells (Figures 4C and 4G, column 4).

To further assess the functional consequences of NF- κ B inhibition, the I κ B-E3 inhibitory peptide was microinjected into primary human vascular endothelial cells (HUVEC; Chen et al, *J. Immunol* 155:3538, 1995). These cells respond to TNF α stimulation by surface expression of NF- κ B regulated adhesion proteins, such as E-selectin. HUVEC cells were plated, microinjected and stimulated as described above. Three hours post stimulation the cells were fixed and stained for expression of the NF- κ B dependent E-selectin. 75%-85% of the HUVEC cells were intensely stained for E-selectin following TNF α stimulation in several experiments. Microinjection of the pp21 peptide resulted in the inhibition of E-selectin expression in 70%-80% of the microinjected cells (Figure 4D; and Figure 4H, column 3). In contrast, the control pp-Fos peptide had no effect on E-selectin expression, as compared to non-microinjected cells (Figures 4F and 4H, column 4). Microinjection of a control, S32/36A substituted I κ B α peptide had no effect on the rate of E-selectin expression.

These results demonstrate that the subunit-specific degradation of the signal-induced phosphorylated I κ B α and I κ B β is mediated by a specific E3. The recognition domain for E3 ubiquitin ligase is a short sequence, centered around the two signal-acquired phosphoserines conserved in both I κ Bs, representing the first biologically relevant E3 recognition motif. The specificity in I κ B recognition is supported by the context of the phosphorylated substrate: an associated cellular complex masks the substrate from non-specific E3s. This feature restricts the NF- κ B inhibitor degradation to the post-stimulation phase, at which it is exposed through site-specific phosphorylation event(s) to the specific ligase. NF- κ B activation and its resultant function can be specifically abolished by *in vivo* inhibition of the I κ B ligase, using a modulating agent as provided herein.

Example 4

Further Characterization of I κ B α Ubiquitination

This Example further illustrates the characterization of the ubiquitin ligase associated with I κ B α ubiquitination.

A. Cytokine Stimulation Promotes the Association Between pI κ B α and a Specific Ubiquitin-Ligase

To further study the recruitment of components of the ubiquitin machinery by phosphorylated I κ B α -complexes, pI κ B α /NF- κ B complexes were purified from proteasome inhibited, TNF- α stimulated HeLa cells, and their

ubiquitination potential was evaluated. HeLa cells were pre-incubated with the proteasome inhibitor ALLN (150 μ M) for 1 hour and stimulated for 10 minutes with TNF α . I κ B α /NF- κ B complexes were immunoaffinity-purified with goat anti-Rel A (p65) antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and the cognate p65 peptide (ELFPLIFPAEPAQASGP (SEQ ID NO:21), which was synthetic and purchased from Alfa-Diagnostic, Inc., and then HPLC-purified, analyzed by mass spectrometry, verified for the predicted structure and proven to be over 85% pure).

The immunopurified fraction was supplemented with various components of the ubiquitin system and subjected to *in vitro* ubiquitination. In particular, the fraction was supplemented with 0.2 μ g purified E1 and 1 μ g purified recombinant UBC5C (Jensen et al., *J. Biol. Chem.* 270:30408-30414, 1995) and incubated for 90 minutes at 37°C in reaction buffer containing: 50mM Tris (pH 7.6), 2mM MgCl₂, 1mM DTT, 20nM okadaic acid, 1mg/ml bovine ubiquitin (Sigma) and 5mM ATP γ S (Sigma). The reaction mix was then boiled in SDS-buffer and the sample analyzed by SDS-PAGE (8.5%) and phospho-imaging.

The addition of ubiquitin, purified E1 and a specific E2, UBC5C, was found to be sufficient to generate the full capacity I κ B α -ubiquitin conjugating activity (Figure 5, lane 2), evident in the accumulation of high-molecular mass species that reacted with I κ B α specific antisera. This activity was E1-dependent (compare lanes 1 and 2), and was not provided by the corresponding immunopurified fraction from non-stimulated HeLa cells (compare lanes 4, 5, 6). As the stimulated HeLa fraction contained both phosphorylated and non-phosphorylated I κ B α , the observed conjugates could be derived from either I κ B species.

To determine the source of the I κ B α -conjugates, the ubiquitination reactions were performed in the presence of a pI κ B α peptide (pp12; CDRHDS[PO3]GLDS[PO3]; SEQ ID NO:22) (lane 7) or a serine/glutamic-acid substituted I κ B α peptide (p12S/E) (lane 8). Both peptides were synthetic, purchased from Alfa-Diagnostic, Inc., and then HPLC-purified, analyzed by mass spectrometry, verified for the predicted structure and proven to be over 85% pure. I κ B α peptides were added at the indicated concentrations to the reaction mixtures in the presence of the peptidase inhibitor Bestatin (40 μ g/ml). Only pp12 abolished the formation of polyubiquitin-I κ B α conjugates, indicating that ubiquitination was specific for pI κ B α (Yaron et al., *EMBO J.* 16:6486-6494, 1997).

B. Phosphorylation is Necessary and Sufficient to Recruit Specific Ubiquitin-Ligase Activity

The finding that E1 and E2 specifically complemented pIkB α -conjugation of the stimulated HeLa fraction, but failed to complement a non-stimulated
5 fraction, could be explained in several ways: a) HeLa stimulation activates a specific pIkB-ubiquitin ligase, b) HeLa stimulation modifies the substrate, thus rendering it liable to ubiquitination, or c) HeLa stimulation is necessary for modifying both the substrate and the ligase. To distinguish among these possibilities, a recombinant, constitutively active IKK2 protein (IKK2-EE) was used (Mercurio et al., *Science*
10 278:860-66, 1997). This protein phosphorylates IkB α at serine 32/36 similarly to a TNF α activated IKK-complex.

Following immunoprecipitation of 35 S-labeled IkB α /NF- κ B complexes from a non-stimulated HeLa lysate previously incubated with recombinant 35 S-labeled IkB α , the complexes were phosphorylated by the recombinant IKK2-EE, eluted with
15 the p65 cognate peptide and subjected to *in vitro* ubiquitination. After incubation with IKK2-EE, nearly all of the 35 S-IkB was phosphorylated. Yet, the addition of ubiquitin, E1 and UBC5C did not result in pIkB α phosphorylation (Figure 6, lane 2). Therefore, IkB phosphorylation by IKK was not sufficient to promote its ubiquitination in the presence of E1 and E2. Conceivably, pIkB α ubiquitination requires an additional
20 component of the HeLa lysate that was not co-immunopurified from non-stimulated cells.

To confirm this hypothesis, immuno-bound IkB α /NF- κ B complexes were incubated with a non-stimulated HeLa lysate, either directly or following IKK2-EE phosphorylation, washed extensively with high-salt buffer and eluted with the p65
25 peptide. Indeed, incubation of the phosphorylated IkB complexes (Figure 6 lane 3), but not of the non-phosphorylated ones (lane 1), with the HeLa lysate, provided the pIkB-ligase component(s) necessary for pIkB α conjugation. No signal was obtained when E1 or E2 were omitted from the reaction, confirming that the signal at the top of the gel represents poly-ubiquitin IkB α -conjugates (lanes 5, 6). TNF α stimulated HeLa-lysate
30 was not superior over a non-stimulated lysate in providing the necessary ligase component.

The inhibitory effect of pp12 on pIkB α -ubiquitination (Figure 5) suggested that the essential HeLa component associates specifically and stably with the pIkB α recognition motif during the incubation period and later functions in pIkB-
35 ubiquitin conjugation. To test this assumption, we included in the incubation step pp12 or the control peptide p12S/E, which was removed together with the HeLa lysate,

before eluting the fractions. The addition of pp12 (Figure 6, lane 4), but not of p12S/E (lane 5), abrogated the ubiquitin-ligase activity associated with the plkB-complex, while preserving the integrity of the substrate. This was evident in the ability of the peptide-treated fractions to undergo ubiquitination in the presence of Reticulocyte
5 Fraction II as an E3 source (Alkalay et al., *Mol. Cell Biol.* 15:1294-301, 1995). Several conclusions may be drawn from this experiment:

- 1) A ubiquitin-ligase component essential to plkB α ubiquitination is recruited by the I κ B α /NF- κ B complex from the HeLa lysate following IKK phosphorylation.
- 10 2) This conjugation-promoting component is contained in a non-stimulated HeLa lysate, indicating that there is no need to activate the ubiquitin-ligase by TNF-stimulation.
- 3) The essential ligase component is apparently specific and associates with I κ B through a direct interaction with the plkB recognition motif (proved by pp12
15 inhibition of plkB α -conjugation).

C. Isolation of the Specific Ubiquitin-Ligase Component that Recognizes plkB α

HeLa extract (250mg) was incubated with 250 μ l anti-p65 immunobeads. Following four washes in buffer A (1M KCl, 0.5 % NP40, 50mM Tris
20 buffer pH 7.6, 1mM DTT) and one wash in buffer B (50mM Tris buffer, pH 7.6, 1mM DTT), half the beads were subject to *in vitro* phosphorylation with IKK and half underwent mock-phosphorylation. The beads were washed twice in buffer A and once in buffer B, agitated with 100mg HeLa extract in the presence of 1 μ M okadaic acid for 30 min at 25°C, washed four times with buffer A, once in buffer A and eluted with
25 1mg/ml p65 peptide. A similar experiment was performed with 10 mg ³⁵S-metabolically-labeled HeLa cell lysate (100 μ Ci/ml Met/Cys for 8 hours) and 25 μ l p65-immunobeads. Eluate-fractions derived from both the hot and cold lysates were mixed, boiled in SDS-sample buffer and analyzed by 7.5% SDS-PAGE and autoradiography. Gel slices corresponding to the autoradiogram signals were excised and their protein-
30 bands sequenced by mass-spectrometry, as described below.

Three immunoaffinity-purified fractions were compared by SDS-page analysis (Figure 7A): 1) a fraction containing I κ B α /NF- κ B complexes that was not phosphorylated by IKK2-EE, but incubated with HeLa lysate; 2) a fraction subjected to IKK2-EE phosphorylation and subsequent incubation with HeLa lysate; 3) a fraction
35 phosphorylated by IKK2-EE, but not incubated with HeLa lysate. All incubations were

performed on immunobead-immobilized complexes, which were then extensively washed and eluted with the p65 peptide.

SDS-PAGE analysis of the three fractions revealed pattern-changes due to IKK phosphorylation or to further immuno-adsorption of I κ B α /NF- κ B proteins, but
5 did not discern any protein recruited to the I κ B-complex following IKK phosphorylation. The complexity of the protein staining could obscure the presence of any recruited protein migrating along with an immunopurified protein. To identify the recruited protein, mass-spectrometry analysis was performed on a dozen Colloidal Blue-stained bands derived from fractions 1 and 2. This analysis revealed the presence
10 of nearly the full spectrum of the Rel family proteins and I κ B α : NF- κ B1 (p105), NF- κ B2 (p100), RelA (p65), p50, p49, C-Rel, I κ B α and I κ B ϵ . Only a few other proteins were co-immunoprecipitated with the I κ B/NF- κ B complex, particularly GRP78/Bip, Hsp 70 and Hsc 70.

To circumvent the possible masking of the putative pI κ B-ubiquitin
15 ligase, we replaced the ligase source with 35 S-biosynthetically-labeled HeLa lysate and traced the I κ B α -associated proteins by SDS-PAGE analysis and autoradiography (Figure 7B). In parallel, the various fractions were tested for their ubiquitin-ligase capacity. The band-pattern of the active fraction (lane 2) was compared with that of the non-active one (lane 1). Four 35 S-protein bands with a molecular mass of 54, 58, 61
20 and 64 kD were distinguished in lane 2. Some of these protein bands could represent components of the ubiquitin ligase that recognizes pI κ B α directly whereas others might have associated with pI κ B α indirectly or with another component of the IKK-phosphorylated complex. To sort out the ligase component that recognizes pI κ B α directly, pp12 or the control peptide p12S/E was added to the radiolabeled HeLa lysate,
25 which was then incubated with the immuno-bound I κ B α /NF- κ B complex. A comparison of the eluted fractions showed that of the four distinctive bands present only in fraction 2, three bands were eliminated by the specific pp12 peptide (p54, p58 and p61), whereas only the 64 kD band persisted in the presence of pp12 (Figure 7B, compare lanes 2 and 3). The control peptide did not affect the association of any of the
30 distinctive proteins with pI κ B α (lane 4). Two of the pI κ B α interacting proteins, p58 and p54, were consistently present and always associated with the specific ubiquitin-ligase activity.

Example 5

Identification of Human E3 Ubiquitin Ligase

This Example illustrates the isolation and characterization of human E3
5 ubiquitin ligase.

The 54 and 58 kD bands described in the previous Example were excised from a ligase-positive and a ligase-negative (HeLa lysate incubated with a non-phosphorylated I κ B α -complex) lane, the proteins digested *in situ* (Shevchenko et al., *Anal. Chem.* 68:850-858, 1996) and the tryptic peptides thus obtained were sequenced
10 by nanoelectrospray mass spectrometry (Wilm et al., *Nature* 379:466-469, 1996). Protein bands were reduced in-gel, S-alkylated and digested in-gel with an excess of trypsin (overnight at room temperature) as described (Shevchenko et al., *Anal. Chem.* 68:850-858, 1996; Wilm et al., *Nature* 379:466-469, 1996). Pieces of gel were extracted and the resulting peptide mixtures were concentrated and desalted, using a
15 micro-column containing 50 nl of Poros R2 material (Perceptive Biosystems, Framingham, MA). Peptides were eluted with 1 μ l of 60% methanol, 5% formic acid directly into a nanoelectrospray needle. Nanoelectrospray spectra were recorded on a quadrupole time-of-flight mass spectrometer (QqTOF, Perkin-Elmer Sciex, Toronto, Canada). Peptide sequence tags (Mann and Wilm, *Anal. Chem.* 66:4390-4399, 1994)
20 were assembled from fragmentation spectra and searched against a non redundant protein sequence database (nrdb) maintained at the European Bioinformatics Institute (EBI, Hinxton Park, England) using the program PeptideSearch (Mann and Wilm, *Anal. Chem.* 66:4390-4399, 1994).

Mass spectra of the 54 kD gel band revealed a complex peptide mixture
25 (Figure 8A) from which several peptides were selected for fragmentation. Proteins identified by peptide sequence tag searching (Mann and Wilm, *Anal. Chem.* 66:4390-4399, 1994) included NF- κ B1 (p50), I κ B kinase α , I κ B ϵ , RelB, tubulin beta-1 chain, and thyroid receptor initiator binding protein. To identify the protein associated with the E3 activity, additional peptides, present in small amounts, were selected for
30 sequencing by comparing the spectrum of the 54 kD bands from the active fraction with that of a similar band from the non-active one (Figure 8B). The peptide sequence tag (1587.81) VVNV (SEQ ID NO:23) (1999.09) was derived from the fragmentation spectrum shown in Figure 8C and unambiguously identified as AAVNVVDFDDKYIVSAS (SEQ ID NO:24). Further spectra identified the peptides
35 LEGHEELVR (SEQ ID NO:25), LVVSGSSDNTIR (SEQ ID NO:26), IQDIETIESNWR (SEQ ID NO:27) and VISEGMLWK (SEQ ID NO:28). The first

four fragments have sequences present within the human F-box/WD protein β -TrCP (Margottin et al., *Mol. Cell* 1:565-574, 1998). However, the fifth peptide (VISEGMLWK (SEQ ID NO:28)) matches that of a peptide from the Drosophila Slimb protein (*see* Jiang and Struhl, *Nature* 391:493-496, 1998), which is highly homologous to human β -TrCP. Further sequencing identified the human E3 ubiquitin ligase nucleotide sequence provided in Figure 9 (SEQ ID NO:15), and the predicted protein sequence provided in Figure 10 (SEQ ID NO:16). Thus, the human E3 ubiquitin ligase appears to be a novel member of the β -TrCP/Slimb family of homologous proteins.

10

Example 6

Further Characterization of E3 Ubiquitin Ligase Activity

This Example further illustrates the ubiquitin ligase activity of the human E3 ubiquitin ligase family members β -TrCP and Slimb.

15

The ability of these proteins to bind $\text{pI}\kappa\text{B}\alpha$ specifically and assist in its ubiquitination was examined in a cell-free system. The $\text{I}\kappa\text{B}\alpha/\text{NF-}\kappa\text{B}$ complex was immunopurified from HeLa cells and the immune complex was either phosphorylated with IKK2-EE or mock-phosphorylated as described above. It was then incubated with the following immobilized FLAG-tagged E3 family members immunoprecipitated from transfected 293 cells: mouse β -TrCP (m β -TrCP), human β -TrCP (h β -TrCP), human β -TrCP with a deletion of the F box region residues 122-168 ($\Delta\beta$ -TrCP) and the Drosophila Slimb protein. The bound material was analyzed by Western blotting with anti- $\text{I}\kappa\text{B}\alpha$ and anti-FLAG antibodies. All of these proteins exclusively bound IKK-phosphorylated, but not mock-phosphorylated, $\text{I}\kappa\text{B}\alpha$ (*see* Figure 11A). However, the human and mouse β -TrCP bound $\text{I}\kappa\text{B}\alpha$ far better than the highly homologous Drosophila protein (compare lanes 2, 4, 6 and 8). $\Delta\beta$ -TrCP bound $\text{pI}\kappa\text{B}\alpha$ even better than the wild type protein, indicating that the F-box region was dispensable for binding. Furthermore, β -TrCP binding was abrogated by a peptide representing the $\text{pI}\kappa\text{B}\alpha$ recognition motif (pp10; DRHDS(PO₃)GLDS(PO₃)M (SEQ ID NO:29); *see* Figure 11B, lane 3), but not by the control peptide (lane 4), specifying the site of $\text{pI}\kappa\text{B}\alpha$ recognition of the conserved DS(PO₃)GLDS(PO₃) (SEQ ID NO:30) sequence.

To evaluate the effect of binding on ubiquitination, the E3 family members and the deletion mutant were used as a source of E3 activity in $\text{pI}\kappa\text{B}\alpha$ ubiquitination. In the presence of E1 and E2 (UBC5C), the wild type β -TrCP proteins facilitated the ubiquitination of $\text{pI}\kappa\text{B}\alpha$, but not of the non-phosphorylated $\text{I}\kappa\text{B}\alpha$ (*see* Figure 11C, lanes 1-4). $\Delta\beta$ -TrCP, devoid of the F-box protein-protein interaction

module, failed to promote ubiquitination (lanes 7 and 8), in spite of its binding capacity (Figure 11A, lane 6). Although Slimb facilitated some $\text{pI}\kappa\text{B}\alpha$ ubiquitination, it was at least ten-fold less efficient than the human and mouse β -TrCP (based on similar FLAG-tag expression levels), corresponding to its weaker activity.

5 The modular design of these family members and the *in vitro* analysis described herein suggested that deletion of the F-box would result in a protein that functions as a dominant negative molecule *in vivo*. In fact, transient over-expression of the $\Delta\beta$ -TrCP inhibited the degradation of endogenous $\text{I}\kappa\text{B}\alpha$ in stimulated Jurkat cells, resulting in accumulation of $\text{pI}\kappa\text{B}\alpha$ (Figure 12A). Consequently, activation of NF- κ B
10 was inhibited (Figure 12B). NF- κ B activation was specific, as $\Delta\beta$ -TrCP did not affect activation of an NF-AT reporter. Of note is the fact that NF- κ B inhibition was also observed with wild type Slimb, whereas the expression of wild type human β -TrCP was not inhibitory (Figure 12B). Therefore, overexpression of wild type Slimb has a dominant negative effect on NF- κ B activation, probably linked to its relatively poor
15 $\text{pI}\kappa\text{B}\alpha$ ubiquitination activity (Figure 11B).

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

20 SUMMARY OF SEQUENCE LISTING

- SEQ ID NO:1 is amino acid sequence of $\text{I}\kappa\text{B}\alpha$
- SEQ ID NO:2 is DNA sequence of $\text{I}\kappa\text{B}\alpha$
- SEQ ID NO:3 is amino acid sequence of $\text{I}\kappa\text{B}\beta$
- SEQ ID NO:4 is DNA sequence of $\text{I}\kappa\text{B}\beta$
- 25 SEQ ID NO:5 is amino acid sequence of pp7
- SEQ ID NO:6 is amino acid sequence of pp11
- SEQ ID NO:7 is amino acid sequence of pp15
- SEQ ID NO:8 is amino acid sequence of pp19
- SEQ ID NO:9 is amino acid sequence of pp21
- 30 SEQ ID NO:10 is amino acid sequence of phospho-Fos peptide
- SEQ ID NO:11 is amino acid sequence of pp21 S/A
- SEQ ID NO:12 is amino acid sequence of HA-tagged $\text{I}\kappa\text{B}\alpha$
- SEQ ID NO:13 is amino acid sequence of HA-tagged S32, 36 $\text{I}\kappa\text{B}\alpha$
- SEQ ID NO:14 is amino acid sequence of HA-tagged $\text{I}\kappa\text{B}\beta$
- 35 SEQ ID NO:15 is DNA sequence of human E3 ubiquitin ligase

- ligase
- SEQ ID NO:16 is predicted amino acid sequence of human E3 ubiquitin
- SEQ ID NO:17 is DNA sequence of human β -TrCP
- SEQ ID NO:18 is amino acid sequence of human E3 β -TrCP
- 5 SEQ ID NO:19 is phosphorylation site of I κ B α
- SEQ ID NO:20 is retrieved β -TrCP sequence
- SEQ ID NO:21 is amino acid sequence of cognate p64 peptide
- SEQ ID NO:22 is amino acid sequence of pI κ B α peptide pp12
- SEQ ID NO:23 is peptide sequence tag of human E3 ubiquitin ligase
- 10 SEQ ID NO:24 is peptide from human E3 ubiquitin ligase
- SEQ ID NO:25 is peptide from human E3 ubiquitin ligase
- SEQ ID NO:26 is peptide from human E3 ubiquitin ligase
- SEQ ID NO:27 is peptide from human E3 ubiquitin ligase
- SEQ ID NO:28 is peptide from human E3 ubiquitin ligase
- 15 SEQ ID NO:29 is amino acid sequence of pI κ B α recognition motif
- SEQ ID NO:30 is conserved pI κ B α sequence

CLAIMS

1. An isolated polypeptide having the sequence recited in SEQ ID NO:16 or a variant thereof that differs in one or more amino acid deletions, insertions or substitutions at no more than 20% of the residues in SEQ ID NO:16, such that the polypeptide enhances ubiquitination of phosphorylated I κ B.
2. An isolated polypeptide comprising a portion of a human E3 ubiquitin ligase recited in SEQ ID NO:16 or variant thereof, wherein the portion binds to phosphorylated I κ B and inhibits ubiquitination of phosphorylated I κ B.
3. An isolated polynucleotide that encodes a polypeptide according to claim 1, wherein the polynucleotide does not encode a full length human E3 ubiquitin ligase.
4. An isolated polynucleotide that encodes a polypeptide according to claim 2.
5. An antisense polynucleotide comprising at least 10 consecutive nucleotides complementary to a polynucleotide according to claim 3.
6. An expression vector comprising a polynucleotide according to any one of claims 3-5.
7. A host cell transformed or transfected with an expression vector according to claim 6.
8. A pharmaceutical composition, comprising:
 - (a) a human E3 ubiquitin ligase polypeptide, wherein the polypeptide comprises a sequence recited in SEQ ID NO:16 or a portion or variant thereof that differs in one or more amino acid insertions, deletions, additions or substitutions at no more than 20% of the residues in SEQ ID NO:16, such that the polypeptide enhances ubiquitination of phosphorylated I κ B; and
 - (b) a physiologically acceptable carrier.

9. A pharmaceutical composition, comprising:
 - (a) a human E3 ubiquitin ligase polypeptide, wherein the polypeptide comprises a portion of a sequence recited in SEQ ID NO:16, or variant thereof that differs in one or more amino acid substitutions, insertions, deletions or additions, such that the polypeptide binds to phosphorylated I κ B and inhibits ubiquitination of phosphorylated I κ B; and
 - (b) a physiologically acceptable carrier.
10. A pharmaceutical composition, comprising:
 - (a) a polynucleotide encoding a human E3 ubiquitin ligase polypeptide, wherein the polypeptide comprises a sequence recited in SEQ ID NO:16 or a portion or variant thereof that differs in one or more amino acid insertions, deletions, additions or substitutions at no more than 20% of the residues in SEQ ID NO:16, such that the polypeptide enhances ubiquitination of phosphorylated I κ B; and
 - (b) a physiologically acceptable carrier.
11. A pharmaceutical composition, comprising:
 - (a) a polynucleotide encoding a human E3 ubiquitin ligase polypeptide, wherein the polypeptide comprises a portion of a sequence recited in SEQ ID NO:16, or variant thereof that differs in one or more amino acid substitutions, insertions, deletions or additions, such that the polypeptide binds to phosphorylated I κ B and inhibits ubiquitination of phosphorylated I κ B; and
 - (b) a physiologically acceptable carrier.
12. A pharmaceutical composition, comprising:
 - (a) an antisense polynucleotide according to claim 5; and
 - (b) a physiologically acceptable carrier.
13. An isolated antibody, or antigen binding fragment thereof, that binds to a human E3 ubiquitin ligase sequence recited in SEQ ID NO:16.
14. An antibody or fragment thereof according to claim 13, wherein the antibody is a monoclonal antibody.

15. A pharmaceutical composition comprising an antibody or fragment thereof according to claim 13, in combination with a physiologically acceptable carrier.

16. For use in the manufacture of a medicament for modulating NF- κ B activity in a patient. A patient pharmaceutical composition according to any one of claims 8-12 or 15, for use in the manufacture of a medicament.

17. For use in the manufacture of a medicament for treating a patient afflicted with a disorder associated with NF- κ B activation. A pharmaceutical composition according to any one of claims 8-12 or 15, for use in the manufacture of a medicament.

18. A composition according to claim 17, wherein the disorder is selected from the group consisting of inflammatory diseases, autoimmune diseases, cancer and viral infection.

19. A method for screening for an agent that modulates NF- κ B activity, comprising the steps of:

(a) contacting a candidate agent with a human E3 ubiquitin ligase polypeptide, wherein the polypeptide comprises a sequence recited in SEQ ID NO:16 or a portion or variant thereof that differs in one or more amino acid substitutions, insertions, deletions or additions, such that the polypeptide enhances ubiquitination of phosphorylated I κ B, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent; and

(b) subsequently evaluating the ability of the polypeptide to enhance ubiquitination of phosphorylated I κ B, relative to a predetermined ability of the polypeptide to enhance ubiquitination of phosphorylated I κ B in the absence of candidate agent; and therefrom identifying an agent that modulates NF- κ B activity.

20. A method according to claim 19, wherein the candidate agent is a small molecule present within a combinatorial library.

21. A method for modulating NF- κ B activity in a patient, comprising administering to a patient a polypeptide comprising a β -TrCP protein (SEQ ID NO:18), or a portion or variant thereof that differs in one or more amino acid insertions, deletions,

additions or substitutions at no more than 20% of the residues in SEQ ID NO:18, such that the polypeptide enhances ubiquitination of phosphorylated I κ B, and thereby modulating NF- κ B activity in the patient.

22. For use in the manufacture of a medicament for treating a patient afflicted with a disorder associated with NF- κ B activation. A therapeutically effective amount of a polypeptide comprising a β -TrCP protein (SEQ ID NO:18), or a portion or variant thereof that differs in one or more amino acid insertions, deletions, additions or substitutions at no more than 20% of the residues in SEQ ID NO:18, the polypeptide enhancing ubiquitination of phosphorylated I κ B, for use in the manufacture of a medicament.

23. A polypeptide according to claim 22, wherein the disorder is selected from the group consisting of inflammatory diseases, autoimmune diseases, cancer and viral infection.

24. A method for screening for an agent that modulates NF- κ B activity, comprising the steps of:

(a) contacting a candidate agent with a polypeptide comprising a β -TrCP protein (SEQ ID NO:18), or a portion or variant thereof that differs in one or more amino acid insertions, deletions, additions or substitutions at no more than 20% of the residues in SEQ ID NO:18, such that the polypeptide enhances ubiquitination of phosphorylated I κ B, under conditions and for a time sufficient to permit interaction between the polypeptide and candidate agent; and

(b) subsequently evaluating the ability of the polypeptide to enhance ubiquitination of phosphorylated I κ B, relative to a predetermined ability of the polypeptide to enhance ubiquitination of phosphorylated I κ B in the absence of candidate agent;

and therefrom identifying an agent that modulates NF- κ B activity.

25. A method according to claim 24, wherein the candidate agent is a small molecule present within a combinatorial library.







FIG. 1A

B**C****D****FIG. 1B-1D**




FIG. 2





FIG. 3A and 3B




FIG. 4A-4C



FIG. 4D-4F




FIG. 4G and 4H




FIG. 5




FIG. 6




FIG. 7A and 7B




FIG. 8A-8D

GCAGAGCGGGGCGCGGGGCGCCATGGAGCCCGACTCGGTGATTGAGGACAAGACCATCGAGCTCATGTGTTCTGTGC
CAAGGTCTTTGTGGCTAGGCTGCGCCAACCTGGTAGAGAGCATGTGCGCACTGAGTTGCC
TGCAGAGCATGCCAGTGTGAGATGTCTCCAGATAAGTAATGGAACATCATCTGTGATCGTCTCCAGAAA
GAGGCCATCAGAAGGAACTATCAAAAAGAAAAGACTTGTGTATTAATATTTTGACCAGTGGTCTGAA
TCAGATCAAGTGAATTTGTGGAACATCTTATTCACGAATGTGTCATTATCAGCATGGACATATTAAC
CTTACCTGAAGCCCATTGTGCAGCGGGACTTTATTACCGCTTTACCAGAGCAAGGCTTAGATCACATAGC
AGAAAACATTCTTTCTACCTGGATGCCAGGTCTCTGTGTGCAGCAGAGCTGGTATGTAAAGAATGGCAG
CGAGTGATCTCAGAAGGAATGCTTTGGAAGAAGCTGATTGAACGAATGGTACGCACTGATCCCTATGGA
AAGGACTTTCAGAAAGAAGAGGGTGGGATCAGTACCTGTTTAAAAACAGACCCACAGATGGCCCTCCAAA
TTCATTTTATAGGTCAATTATACCCAAAGATTATCCAGGATATAGAGACTATAGAATCTAACTGGCGGTGT
GGACGACACAACCTTGACAGAGGATTCAGTGCCGCTCTGAAAATAGTAAAGGTGTCTACTGTTTACAGTACG
ATGATGAAAAATTATCAGTGGCCTACGAGATAATTCTATTAAGATATGGGATAAAACAGCCTGGAATG
TTTGAAGTGTTAACAGGACACACAGGCTCTGTCCCTGTCTGCACTATGATGAGCGTGCATTGTAACT
GGCTCTTCAGATTCTACGGTGAGAGTGTGGGATGTGAACACGGGTGAAGTTCTTAACACATTGATCCACC
ACAAATGAGGCTGTATTGCACCTACGCTTCAGCAATGGACTGATGGTGACCTGTTCCAAGGACCGCTCCAT
TGCTGTGTGGGACATGGCTTCTGCGACCGACATCACTTACGCCGTGTCTGGTGGCCACCGGGCTGCC
GTCAATGTAGTAGACTTTGACGACAAGTACATCGTGTCTGCCCTGGTGACAGGACCATCAAAGTCTGGA
GCACGAGCAGCTGTGAATTTGTCGTACTCTCAATGGGCACAAGCGGGGCATTGCCTGTCTCCAGTACAG
GGATCGCCTGGTTGTAGTGGATCATCAGATAATACCATTAGGCTCTGGGATATTGAATGTGGTGCCCTGT
TTAAGAGTCTAGAGGGACATGAAGAATTGGTCCGATGCATCCGGTTTGATAACAAGAGGATTGTCAAGT
GGCCCTATGATGGGAAAATTAAAGTTTGGGACTTGCAAGCTGCTCTTGACCTCGAGCCCCAGCAAGCAC
ATTGTGTTTGCGCACATTGGTGAACATTCTGGACGTGTGTTTGGCTCCAGTTTGATGAGTTTCAGATC
ATCAGCAGCTCCCATGATGACACTATTTTGATTGGGATTCTTAAATGTGCCCTCCAGTGCCCAGAATG
AGACCCGTTCTCCCTCCAGAACATACACTTACATCTCTAGATAACAGTCTGCACTTTCACCCGTTTCAGG
GTTTTCTAGTCTTGAAGTACTGGCTACGTGGCTACCAATGCCTAAGGGAGTTCCGTTACAGCTGAGTTA
TGAAGCTGGAAATGGTTCTAGACGCTGGGTAGATGCAAGCAGCCCTAACTCTCAAGTACCGACATTTCT
CACCTCTGATCCGGCTCTCCTTTGAGAAGGAGACCTTAGCTTCCCGGGCTTCAAGTAGAACAGAAAGCCC
GTTTCCCTCCCTCATCAGTGAAAAATCTAATGTTTCAAATGTAATTGTTTATAGAAAAGGAACATAGA
ATCTGTTTTACAGAAATGTAATCGACCGTCAAGAGAAGACTTGGCTCTAATTTATATTGCTTTGCACCTT
GGTTTGATTAAGAAACAGCATTCTTCTCAGTGAAATTTGGGTGCCAAACACCTACCCAGAATGTCC
AGGGCTTTCATTTTCAAAGTTAGCATTCTCTTTGACCGTCCAAGTCATTATGAATCTGACTTGTG
TATTAGGAACATGTTGGACAGTGGAAAATTTCTCTGGATTGTTTATAGTAATTTTGGGATTATACTT
CCTTCTGTACCAATTTCTTTAATTTAAAGAACTATAAGTCAGTTATATTATCTACCAACAGGTAATAT
AGCTCTTTCTTTTAACTGTCTCTGTGCCCCAACCATCTCTGATATTTGGTAGAGTAACACCTTTA
TACGTGTGCTTGCCTCTAATTTAAATACTGTATTCGCATGTAGATATAATGTACATAACAGTTTAAAC
TCAAAGTTGCTGGAGTCAGGGCCCCCTGTGCTTGAGACACTAATACAGAGTGTGTTGCACTTAGCCATG
GGCTGGGCTCAAGAACCTGATACCTGGGTTGATGTGGATTACCTAGAACCCTTCTGCAGTATTCATACA
GTGTTTTTATTTGTTGTTGTCATTGCGTGTGTGGTTGTGTGTTTTAATGAGAATCTTGTTTTA
AAATGTAATTTCTAAGGTTTAAACCCAAATGTTTTATTGTTGTGGAGTATATATTACAATAGAGAG
GTACCTTAAACATTTTTGTTCTTATTTCTTTCTCATAAGTACTCCTGAGTACAAGTGGTCACCTCCCA
TAGTATTCATTTGGCTTCGCTGTCAAAAATCATTATCTGTGCAGTCGTGGCCCTGGGAAGGGGAAATAA
GAAGGCCCTGTTGACGGGCTGTCTGGCTCTGGAAATTCATGCATCCTGGCCTTGCCAAGGTTCTGGCAGG
GCCTGCTGGTGTGTTGGAGCCTGCAGGGCAGGTGAGCTGGTTCAGAGGCCCATGCTGAGGGGTGGGTGC
TCTGAAGTGGAGTGAAGCCTCAAGCCCATGAATGCCACCCAGTCATCTCTGGTGTGAGCTGCTGCTGTG
GCCCCAGCAGGTTCTCAAAGCTCCCAAGTCTCCCTACGACACAGCCCAATGTGTAATGGCACTGTTG
CCCTGACAGTGCATGGAAGGACGTTGGCATCCAATTGGCACTCCTTCTCCCTTATTCAATATTAGGTTT
GATTTGCCCTTCGCCATTGTTTCAAAGATCAAGGAATGTCAATAACATTTTAAAGGACCAATAAACAGC
CTCCTATAAAGTAAACCTCTTCCCGTGAAGCACACTCTACTACTAAAGGGAAGGCCCTGGGCTCTGAT
TTGTCTTTGCATTGAGAACGGTGTGGGGATCAGTGTGTGTATGTGATTGTTTATTTAGTTGGCTTT
GCTTTTGTAGTTTTCTTTTAAAAATAAAATCCTTCTTCCCATGTTACTAAATTAATTTATGTTTTGA
GAGGTTGAGTCTCAAAGTGAACAATAAACCTCCATTCAAGGTGGATGTTGTAAGCTTGATGGTGGT
TGTGAAAGTGATTAGCTTTGACCACTTTTCATCTACAGCTTCAATATCAAACCTGGTTAGGAAAGCCCA
GGGGGAAGGGAGGGGGCAGGGGAGGAGCAATTCTGAATGAATGAATGGATTTTTGTTGTTTTGTCATG
TTTAATATAGAAGTCCCCTCGTTCCTTGGGAGATGATGGCTTTGAATATGCAGACAACCTTTGAATTG

FIG. 9A

TGCCTACTAAATTATAGCAGGGGACTTTGGCACCCAAGGAGTTCTGACTTTCTGGGATTATAATAGTAAT
TCCCAGCCATACTCTGGACTTTATTTTGCTAACCATAACTGAGCAAATGTAAATTACTGCTATATTAATG
TTTTAAAGCACTGGGATAGTCTAATTCTAACTTGTAATTAATTATGTTTGCCAATTATCTGTTTGAAATA
AATTTGTGTCTGAACAGCTATTGAAACTGTTAAATTGTACAGATATTATTCATGACAGCTTTGTACTGTG
GAATGTGCTTAATAAAAAACAAAAAGTTTGACTTTTGTCCAGTAAATTGCTAAGTAATGTCAATAAATC
GAGTATGGGTATTATGCAGTGCACCTAATCTGGCTTCATGCAATTGTTACTTCAGCTACTGATTCAAAGC
CAATACTCTTAATAAAGTGTGCAATACTC

MEPDSVIEDKTIELMCSVPRSLWLGCANLVESMCALSCLQSMPSVRCLQISNGTSSVIVSRK
RPSEGN YQKEKDLCIKYFDQWSESDQVEFVEHLJSRMCHYQHGHSYLPMLQRDFITALPEQGLDHA
ENILSYLDARSLCAAELVCKEWQRVISEGMLWKKLIERMVRTDPLWKGLSERRGWDQYLFKNRPTDGPPN
SFYRSLYPKIIQDIETIESNWRCGRHNLQRIQCRSENSKGVYCLQYDDEKIISGLRDNSIKIWDKTSLEC
LKVL TGHTGSVLCLOQYDERVIVTGSSDSTVRVWDVNTGEVLNLIHHNEAVLHLRFSNGLMVTCSKDRSI
AVWDMASATDITLRRVLVGHRAAVNVVDFDDKYIVSASGDRTIKWWSTSTCEFVRTLNHGKRGIAQLQYR
DRLVVGSSDNTIRLWDIECGACLRVLEGHEELVRCIRFDNKRIVSGAYDGKIKVWDLQAALDPRAPAST
LCLRTLVEHSGRVFRLQFDEFQIISSSHDDTILIWDFLNVPPSAQNETRSPSRITYISR








FIG. 11A-11C

*A**B**FIG. 12A and 12B*

SEQUENCE LISTING

<110> Signal Pharmaceuticals, Inc.
Yisum Research Development Company of the Hebrew University of
Jerusalem

<120> COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF
NF-kB

<130> 860098.427PC

<140> PCT

<141> 1999-12-09

<160> 30

<170> PatentIn Ver. 2.0

<210> 1

<211> 317

<212> PRT

<213> Homo sapiens

<400> 1

Met	Phe	Gln	Ala	Ala	Glu	Arg	Pro	Gln	Glu	Trp	Ala	Met	Glu	Gly	Pro
1				5					10					15	

Arg	Asp	Gly	Leu	Lys	Lys	Glu	Arg	Leu	Leu	Asp	Asp	Arg	His	Asp	Ser
	20							25					30		

Gly	Leu	Asp	Ser	Met	Lys	Asp	Glu	Glu	Tyr	Glu	Gln	Met	Val	Lys	Glu
	35						40					45			

Leu	Gln	Glu	Ile	Arg	Leu	Glu	Pro	Gln	Glu	Val	Pro	Arg	Gly	Ser	Glu
	50					55					60				

Pro	Trp	Lys	Gln	Gln	Leu	Thr	Glu	Asp	Gly	Asp	Ser	Phe	Leu	His	Leu
65					70					75					80

Ala	Ile	Ile	His	Glu	Glu	Lys	Ala	Leu	Thr	Met	Glu	Val	Ile	Arg	Gln
			85						90					95	

Val	Lys	Gly	Asp	Leu	Ala	Phe	Leu	Asn	Phe	Gln	Asn	Asn	Leu	Gln	Gln
			100					105					110		

Thr	Pro	Leu	His	Leu	Ala	Val	Ile	Thr	Asn	Gln	Pro	Glu	Ile	Ala	Glu
		115					120					125			

Ala	Leu	Leu	Gly	Ala	Gly	Cys	Asp	Pro	Glu	Leu	Arg	Asp	Phe	Arg	Gly
	130					135					140				

Asn	Thr	Pro	Leu	His	Leu	Ala	Cys	Glu	Gln	Gly	Cys	Leu	Ala	Ser	Val
145					150					155					160

Gly	Val	Leu	Thr	Gln	Ser	Cys	Thr	Thr	Pro	His	Leu	His	Ser	Ile	Leu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

	165		170		175										
Lys	Ala	Thr	Asn	Tyr	Asn	Gly	His	Thr	Cys	Leu	His	Leu	Ala	Ser	Ile
	180							185					190		
His	Gly	Tyr	Leu	Gly	Ile	Val	Glu	Leu	Leu	Val	Ser	Leu	Gly	Ala	Asp
	195						200					205			
Val	Asn	Ala	Gln	Glu	Pro	Cys	Asn	Gly	Arg	Thr	Ala	Leu	His	Leu	Ala
	210						215				220				
Val	Asp	Leu	Gln	Asn	Pro	Asp	Leu	Val	Ser	Leu	Leu	Leu	Lys	Cys	Gly
	225				230					235					240
Ala	Asp	Val	Asn	Arg	Val	Thr	Tyr	Gln	Gly	Tyr	Ser	Pro	Tyr	Gln	Leu
				245					250					255	
Thr	Trp	Gly	Arg	Pro	Ser	Thr	Arg	Ile	Gln	Gln	Gln	Leu	Gly	Gln	Leu
			260					265					270		
Thr	Leu	Glu	Asn	Leu	Gln	Met	Leu	Pro	Glu	Ser	Glu	Asp	Glu	Glu	Ser
	275						280					285			
Tyr	Asp	Thr	Glu	Ser	Glu	Phe	Thr	Glu	Phe	Thr	Glu	Asp	Glu	Leu	Pro
	290						295					300			
Tyr	Asp	Asp	Cys	Val	Phe	Gly	Gly	Gln	Arg	Leu	Thr	Leu			
	305					310				315					

<210> 2

<211> 1550

<212> DNA

<213> Homo sapiens

<400> 2

```

tgcgcgcgtc cgcgcccgcca gcgccccagc gaggaagcag cgcgcagccc gcggcccagc 60
gcacccgcag cagcgcccgc agctogtccg cgccatgttc caggcggccg agcgccccc 120
ggagtgggccc atggagggccc cccgcgacgg gctgaagaag gagcgggtac tggacgaccg 180
ccacgacagc ggcctggact ccatgaaaga cgaggagtac gagcagatgg tcaaggagct 240
gcaggagatc cgctcagcgc cgcaggaggt gccgcgcggc tcggagccct ggaagcagca 300
gtccaccgag gacggggact cgttcctgca cttggccatc atccatgaag aaaaggcact 360
gaccatggaa gtgatccgcc aggtgaaggg agacctggct ttcctcaact tccagaacaa 420
cctgcagcag actccactcc acttggtgtg gatcaccaac cagccagaaa ttgctgaggc 480
acttctggga gctggctgtg atcctgagct ccgagacttt cgaggaaata cccccctaca 540
ccttgctgtg gagcagggtc gcctggccag cgtgggagtc ctgactcagt cctgcaccac 600
cccgcacctc cactccatcc tgaaggctac caactacaat ggccacacgt gtctacactt 660
agcctctatc catggctacc tgggcatcgt ggagcttttg gtgtccttgg gtgctgatgt 720
caatgctcag gagccctgta atggccggac tgcccttcac ctgcagtggt acctgcaaaa 780
tcctgacctg gtgtcactcc tgtgaagtg tggggctgat gtcaacagag ttacctacca 840
gggctattct ccctaccagc tcacctgggg ccgcccgaag acccgatac agcagcagct 900
gggccagctg aactagaaa accttcagat gctgccagag agtgaggatg aggagagcta 960
tgacacagag tcagagtcca cggagtccac agaggacgag ctgccctatg atgactgtgt 1020
gtttggaggc cagcgtctga cgttatgagt gaaaaggggc tgaagaaga tggacttgta 1080
tatttgatca aaaaaaagt tttatttttc taaaaaaga aaaaaaga aaaaatttaa 1140

```

```

agggtgtact tatatccaca ctgcacactg cctagcccaa aacgtcttat tgtggttagga 1200
tcagccctca ttttgttgct tttgtgaact tttgtaggg gacgagaaag atcattgaaa 1260
ttctgagaaa acttctttta aacctcacct ttgtgggggt tttggagaag gttatcaaaa 1320
atttcatgga aggaccacat tttatattta ttgtgcttcg agtgactgac cccagtggta 1380
tcctgtgaca tgtaacagcc aggagtgtta agcgttcagt gatgtggggg gaaaagttac 1440
tacctgtcaa ggtttgtgtt accctcctgt aaatgggtga cataatgtat tgttggtaat 1500
tattttggta cttttatgat gtatatttat taaagagatt ttacaaatg 1550

```

<210> 3

<211> 359

<212> PRT

<213> Homo sapiens

<400> 3

```

Met Ala Gly Val Ala Cys Leu Gly Lys Thr Ala Asp Ala Asp Glu Trp
  1              5              10              15

```

```

Cys Asp Ser Gly Leu Gly Ser Leu Gly Pro Asp Ala Ala Ala Pro Gly
      20              25              30

```

```

Gly Pro Gly Leu Gly Ala Glu Leu Gly Pro Glu Leu Ser Trp Ala Pro
    35              40              45

```

```

Leu Val Phe Gly Tyr Val Thr Glu Asp Gly Asp Thr Ala Leu His Leu
    50              55              60

```

```

Ala Val Ile His Gln His Glu Pro Phe Leu Asp Phe Leu Leu Gly Phe
    65              70              75              80

```

```

Ser Ala Gly His Glu Tyr Leu Asp Leu Gln Asn Asp Leu Gly Gln Thr
      85              90              95

```

```

Ala Leu His Leu Ala Ala Ile Leu Gly Glu Ala Ser Thr Val Glu Lys
    100              105              110

```

```

Leu Tyr Ala Ala Gly Ala Gly Val Leu Val Ala Glu Arg Gly Gly His
    115              120              125

```

```

Thr Ala Leu His Leu Ala Cys Arg Val Arg Ala His Thr Cys Ala Cys
    130              135              140

```

```

Val Leu Leu Gln Pro Arg Pro Ser His Pro Arg Asp Ala Ser Asp Thr
    145              150              155              160

```

```

Tyr Leu Thr Gln Ser Gln Asp Cys Thr Pro Asp Thr Ser His Ala Pro
    165              170              175

```

```

Ala Ala Val Asp Ser Gln Pro Asn Pro Glu Asn Glu Glu Glu Pro Arg
    180              185              190

```

```

Asp Glu Asp Trp Arg Leu Gln Leu Glu Ala Glu Asn Tyr Asp Gly His
    195              200              205

```

```

Thr Pro Leu His Val Ala Val Ile His Lys Asp Ala Glu Met Val Arg
    210              215              220

```

Leu Leu Arg Asp Ala Gly Ala Asp Leu Asn Lys Pro Glu Pro Thr Cys
225 230 235 240

Gly Arg Thr Pro Leu His Leu Ala Val Glu Ala Gln Ala Ala Ser Val
245 250 255

Leu Glu Leu Leu Leu Lys Ala Gly Ala Asp Pro Thr Ala Arg Met Tyr
260 265 270

Gly Gly Arg Thr Pro Leu Gly Ser Ala Leu Leu Arg Pro Asn Pro Ile
275 280 285

Leu Ala Arg Leu Leu Arg Ala His Gly Ala Pro Glu Pro Glu Asp Glu
290 295 300

Asp Asp Lys Leu Ser Pro Cys Ser Ser Ser Gly Ser Asp Ser Asp Ser
305 310 315 320

Asp Asn Arg Asp Glu Gly Asp Glu Tyr Asp Asp Ile Val Val His Ser
325 330 335

Gly Arg Ser Gln Asn Arg Gln Pro Pro Ser Pro Ala Ser Lys Pro Leu
340 345 350

Pro Asp Asp Pro Asn Pro Ala
355

<210> 4

<211> 1212

<212> DNA

<213> Homo sapiens

<400> 4

gcgcaactgga gctcatcgca gagcccagcg acaggcaggg gaccacaggg ggccacccga 60
gggtggctggg gccatggccg gggtcgcggtg cttggggaaa actgcggatg ccgatgaatg 120
gtgcgacagc ggcttgggct ctctaggtcc cgacgcagcg gctcccggag gaccaggtct 180
gggcgcagag cttggcccag agctgtcgtg ggccgacctt gtctttggct acgtcactga 240
ggatggggac acagccctgc acttggctgt gattcatcag catgagccct tcctggattt 300
cctcctgggc ttttccgccc gccacgagta ccttgacctg cagaatgacc taggccaac 360
agccctgcat ctacgagcca tccttgggga ggcatctaca gtagagaagt tgtatgcagc 420
cgggtgcagga gtgttggtgg ctgagagagg gggccacacg gcattgcact tggcctgccg 480
ggtcagggca cacacgtgcg cgtgcgtact gctccagccc cgtcccagcc acccaagaga 540
tgctcagat acctacctca ctacagacca ggactgtacc ccagacacca gccatgcccc 600
tgctgcccgtg gattcccaac ccaacccaga gaacgaagag gagccgcgtg atgaagactg 660
gaggctacaa ctagaagctg aaaactatga tggccatacc ccaactccatg tagctgtcat 720
ccacaaagat gcagagatgg tccggctgct cagggatgcc ggagccgacc tcaataaacc 780
ggagcctacg tgtggccgga cccctctgca cctggcagta gaagcccagg cagccagcgt 840
gctggaactt ctctgaaag ccggtgctga cccaccgcc cgcatgtatg ggggccgcac 900
cccgttggc agtgccctgc tccggcccaa cccatcctt gcccgcctcc tccgtgcaca 960
tggggcccct gaacctgagg acgaggacga taagcttagc ccttgacgca gcagcggcag 1020
cgacagtgc agtgacaaca gagatgaggg cgatgaatat gatgacatcg tggttcacag 1080
tggcaggagc caaaaccgac aaccgccttc cccggcatcc aaacctcttc ctgatgaccc 1140
caacctgcc tgacttaagt gctaataatta atataatttc caacttaata aaattgcaga 1200

cctgacaacc ag

1212

<210> 5

<211> 8

<212> PRT

<213> Homo sapiens

<400> 5

Cys Asp Ser Gly Leu Asp Ser Met

1

5

<210> 6

<211> 12

<212> PRT

<213> Homo sapiens

<400> 6

Cys Asp Asp Arg His Asp Ser Gly Leu Asp Ser Met

1

5

10

<210> 7

<211> 16

<212> PRT

<213> Homo sapiens

<400> 7

Cys Asp Asp Arg His Asp Ser Gly Leu Asp Ser Met Lys Asp Glu Glu

1

5

10

15

<210> 8

<211> 20

<212> PRT

<213> Homo sapiens

<400> 8

Cys Glu Arg Leu Leu Asp Asp Arg His Asp Ser Gly Leu Asp Ser Met

1

5

10

15

Lys Asp Glu Glu

20

<210> 9

<211> 22

<212> PRT

<213> Homo sapiens

<400> 9

Cys Lys Lys Glu Arg Leu Leu Asp Asp Arg His Asp Ser Gly Leu Asp

1

5

10

15

Ser Met Lys Asp Glu Glu

20

<210> 10
<211> 19
<212> PRT
<213> Homo sapiens

<400> 10
Ile Gly Arg Arg Gly Lys Val Glu Gln Leu Ser Pro Glu Glu Glu Glu
1 5 10 15

Lys Arg Arg

<210> 11
<211> 22
<212> PRT
<213> Homo sapiens

<400> 11
Cys Lys Lys Glu Arg Leu Leu Asp Asp Arg His Asp Ala Gly Leu Asp
1 5 10 15

Ala Met Lys Asp Glu Glu
20

<210> 12
<211> 347
<212> PRT
<213> Homo sapiens

<400> 12
Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Met Tyr Pro Tyr Asp Val
1 5 10 15

Pro Asp Tyr Ala Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Met Phe
20 25 30

Gln Ala Ala Glu Arg Pro Gln Glu Trp Ala Met Glu Gly Pro Arg Asp
35 40 45

Gly Leu Lys Lys Glu Arg Leu Leu Asp Asp Arg His Asp Ser Gly Leu
50 55 60

Asp Ser Met Lys Asp Glu Glu Tyr Glu Gln Met Val Lys Glu Leu Gln
65 70 75 80

Glu Ile Arg Leu Glu Pro Gln Glu Val Pro Arg Gly Ser Glu Pro Trp
85 90 95

Lys Gln Gln Leu Thr Glu Asp Gly Asp Ser Phe Leu His Leu Ala Ile
100 105 110

Ile His Glu Glu Lys Ala Leu Thr Met Glu Val Ile Arg Gln Val Lys
 115 120 125
 Gly Asp Leu Ala Phe Leu Asn Phe Gln Asn Asn Leu Gln Gln Thr Pro
 130 135 140
 Leu His Leu Ala Val Ile Thr Asn Gln Pro Glu Ile Ala Glu Ala Leu
 145 150 155 160
 Leu Gly Ala Gly Cys Asp Pro Glu Leu Arg Asp Phe Arg Gly Asn Thr
 165 170 175
 Pro Leu His Leu Ala Cys Glu Gln Gly Cys Leu Ala Ser Val Gly Val
 180 185 190
 Leu Thr Gln Ser Cys Thr Thr Pro His Leu His Ser Ile Leu Lys Ala
 195 200 205
 Thr Asn Tyr Asn Gly His Thr Cys Leu His Leu Ala Ser Ile His Gly
 210 215 220
 Tyr Leu Gly Ile Val Glu Leu Leu Val Ser Leu Gly Ala Asp Val Asn
 225 230 235 240
 Ala Gln Glu Pro Cys Asn Gly Arg Thr Ala Leu His Leu Ala Val Asp
 245 250 255
 Leu Gln Asn Pro Asp Leu Val Ser Leu Leu Leu Lys Cys Gly Ala Asp
 260 265 270
 Val Asn Arg Val Thr Tyr Gln Gly Tyr Ser Pro Tyr Gln Leu Thr Trp
 275 280 285
 Gly Arg Pro Ser Thr Arg Ile Gln Gln Gln Leu Gly Gln Leu Thr Leu
 290 295 300
 Glu Asn Leu Gln Met Leu Pro Glu Ser Glu Asp Glu Glu Ser Tyr Asp
 305 310 315 320
 Thr Glu Ser Glu Phe Thr Glu Phe Thr Glu Asp Glu Leu Pro Tyr Asp
 325 330 335
 Asp Cys Val Phe Gly Gly Gln Arg Leu Thr Leu
 340 345

<210> 13
 <211> 347
 <212> PRT
 <213> Homo sapiens

<400> 13
 Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Met Tyr Pro Tyr Asp Val
 1 5 10 15

Glu Asn Leu Gln Met Leu Pro Glu Ser Glu Asp Glu Glu Ser Tyr Asp
 305 310 315 320

Thr Glu Ser Glu Phe Thr Glu Phe Thr Glu Asp Glu Leu Pro Tyr Asp
 325 330 335

Asp Cys Val Phe Gly Gly Gln Arg Leu Thr Leu
 340 345

<210> 14
 <211> 389
 <212> PRT
 <213> Homo sapiens

<400> 14
 Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Met Tyr Pro Tyr Asp Val
 1 5 10 15

Pro Asp Tyr Ala Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Met Ala
 20 25 30

Gly Val Ala Cys Leu Gly Lys Thr Ala Asp Ala Asp Glu Trp Cys Asp
 35 40 45

Ser Gly Leu Gly Ser Leu Gly Pro Asp Ala Ala Ala Pro Gly Gly Pro
 50 55 60

Gly Leu Gly Ala Glu Leu Gly Pro Glu Leu Ser Trp Ala Pro Leu Val
 65 70 75 80

Phe Gly Tyr Val Thr Glu Asp Gly Asp Thr Ala Leu His Leu Ala Val
 85 90 95

Ile His Gln His Glu Pro Phe Leu Asp Phe Leu Leu Gly Phe Ser Ala
 100 105 110

Gly His Glu Tyr Leu Asp Leu Gln Asn Asp Leu Gly Gln Thr Ala Leu
 115 120 125

His Leu Ala Ala Ile Leu Gly Glu Ala Ser Thr Val Glu Lys Leu Tyr
 130 135 140

Ala Ala Gly Ala Gly Val Leu Val Ala Glu Arg Gly Gly His Thr Ala
 145 150 155 160

Leu His Leu Ala Cys Arg Val Arg Ala His Thr Cys Ala Cys Val Leu
 165 170 175

Leu Gln Pro Arg Pro Ser His Pro Arg Asp Ala Ser Asp Thr Tyr Leu
 180 185 190

Thr Gln Ser Gln Asp Cys Thr Pro Asp Thr Ser His Ala Pro Ala Ala
 195 200 205

Val Asp S r Gln Pro Asn Pro Glu Asn Glu Glu Glu Pro Arg Asp Glu
 210 215 220

Asp Trp Arg Leu Gln Leu Glu Ala Glu Asn Tyr Asp Gly His Thr Pro
 225 230 235 240

Leu His Val Ala Val Ile His Lys Asp Ala Glu Met Val Arg Leu Leu
 245 250 255

Arg Asp Ala Gly Ala Asp Leu Asn Lys Pro Glu Pro Thr Cys Gly Arg
 260 265 270

Thr Pro Leu His Leu Ala Val Glu Ala Gln Ala Ala Ser Val Leu Glu
 275 280 285

Leu Leu Leu Lys Ala Gly Ala Asp Pro Thr Ala Arg Met Tyr Gly Gly
 290 295 300

Arg Thr Pro Leu Gly Ser Ala Leu Leu Arg Pro Asn Pro Ile Leu Ala
 305 310 315 320

Arg Leu Leu Arg Ala His Gly Ala Pro Glu Pro Glu Asp Glu Asp Asp
 325 330 335

Lys Leu Ser Pro Cys Ser Ser Ser Gly Ser Asp Ser Asp Ser Asp Asn
 340 345 350

Arg Asp Glu Gly Asp Glu Tyr Asp Asp Ile Val Val His Ser Gly Arg
 355 360 365

Ser Gln Asn Arg Gln Pro Pro Ser Pro Ala Ser Lys Pro Leu Pro Asp
 370 375 380

Asp Pro Asn Pro Ala
 385

<210> 15
 <211> 4230
 <212> DNA
 <213> Homo sapiens

<400> 15
 gcgaggcggg gccgccgggg ccgccatgga gcccgactcg gtgattgagg acaagaccat 60
 cgagctcatg tgttctgtgc caaggtcttt gtggctaggc tgcgccaacc tggtagagag 120
 catgtgcgca ctgagttgcc tgcagagcat gcccgagtgc agatgtctcc agataagtaa 180
 tggaacatca tctgtgatcg tctccagaaa gaggccatca gaaggaaact atcaaaaaga 240
 aaaagacttg tgtattaaat attttgacca gtggtctgaa tcagatcaag tggaatttgt 300
 ggaacatctt atttcacgaa tgtgtcatta tcagcatgga catattaact cttacctgaa 360
 gcccatgttg cagcgggact ttattaccgc ttaccagag caaggcttag atcacatagc 420
 agaaaacatt ctttcgtacc tggatgccag gtctctgtgt gcagcagagc tggtatgtaa 480
 agaattggcag cgagtgatct cagaaggaat gctttggaag aagctgattg aacgaatggt 540
 acgcactgat cccctatgga aaggactttc agaaagaaga ggggtgggac agtacctgtt 600
 taaaaacaga cccacagatg gccctccaaa ttcattttat aggtcattat acccaaagat 660
 tatccaggat atagagacta tagaatctaa ctggcggtgt ggacgacaca acttgcagag 720

gattcagtgc cgctctgaaa atagtaaagg tgtctactgt ttacagtacg atgatgaaaa 780
aattatcagt ggcctacgag ataattctat taagatatgg gataaaacca gcctggaatg 840
tttgaaagtg ttaacaggac acacaggctc tgtcctctgt ctgcagtatg atgagcgtgt 900
cattgtaact ggctcttcag attctacggg gagagtgtgg gatgtgaaca cgggtgaagt 960
tcttaacaca ttgatccacc acaatgaggc tgtattgcac ttacgcttca gcaatggact 1020
gatgggtgacc tgttccaagg accgctccat tgctgtgtgg gacatggctt ctgcgaccga 1080
catcacttta cgccgtgtcc tgggtggcca cgggctgcc gtcaatgtag tagactttga 1140
cgacaagtac atcgtgtctg cctctgggga caggaccatc aaagtctgga gcacgagcac 1200
ctgtgaattt gttcgtactc tcaatgggca caagcggggc attgcctgtc tccagtacag 1260
ggatcgccctg gttgttagtg gatcatcaga taataccatt aggctctggg atattgaaatg 1320
tgggtgcctgt ttaagagtcc tagagggaca tgaagaattg gtccgatgca tccggtttga 1380
taacaagagg attgtcagtg gggcctatga tgggaaaatt aaagtttggg acttgcaagc 1440
tgctcttgac cctcgagccc cagcaagcac attgtgtttg cgcacattgg tggaaacattc 1500
tggacgtgtg tttcggctcc agtttgatga gtttcagatc atcagcagct ccatgatga 1560
cactattttg atttgggatt tcttaaatgt gcctcccagt gcccagaatg agaccggtc 1620
tccctccaga acatacactt acatctctag ataacagtct gcactttcac ccgtttcagg 1680
gttttctagt cttgaactac tggctacgtg gctaccaaatt gcctaaggga gttcgttcac 1740
agctgagtta tgaagctgga attggttcta gacgctgggt agatgcaaag cagcctaact 1800
cttcaagtac cgacatttct cacctctgat tccggctctc ctttgagaag gagaccttag 1860
cttccccggc ttcaagtaga acagaagccc gtttcttcc ctcatcagtg aaaaaacta 1920
atgtttcaaa tgtaaattgt tcatagaaaa ggaacataga atctgtttta cagaagtaaa 1980
tcgaccgtca agagaagact tggcctctaa tttatattgc tttgcacttt ggtttgatat 2040
taagaaacag cattcttctt cagtgaattt ttgggtgcca aacacctacc cagaatgtcc 2100
agggctttca ttttcaaaag ttagcattct ccttttgacc gtccaagtca ttatgaattc 2160
tgacttggtg tattaggaac atgttggaac gtggaaaatt ttctctggat tgtttlagta 2220
atatttttgg gattatactt cctttctgta ccaatttctt ttaatttaaa gaactataag 2280
tcagttatat tatctaccaa caggtaatat agctcttctt tttattaaact gttctctgtc 2340
cccaaccat ctctgatat ttggtagagt aacaccttta tacgtgtgct tgcctcctaa 2400
tttaaaatac tgtattcgca tgtagatata atgtacataa cagttaaac tcaaagttgc 2460
tggagtccag gcccctgtg cttgagacac taatacagag tgtgttcgca cttagccatg 2520
ggctgggctc aagaacctga tacctgggtt gatgtggatt acctagaacc ctctctgcag 2580
tattcataca gtgtttttat tttgttggtg tcattgctgt tgtgtggttt gtgtgtgttt 2640
ttaatgagaa tcttgtttta aaatgtaatt tctaagggtt aacacaaaaa tgttttattt 2700
gttgtggagt atatatata caatagagag gtaccttaaa cattttttgt tcttattctt 2760
tttctcataa gtactcctga gtacaagtgg tcacctccca tagtattcat ttggcttcgc 2820
tgtcaaaaat cattattctg tgcagtcgtg gccctgggaa ggggaaataa gaaggccctg 2880
ttgacgggct gtcttggtc ttggaattcat gcatcctggc cttgccaagg ttctggcagg 2940
gcctgctggg gtgttgagc ctgcagggca ggtcaggctg gttcagaggc ccatgctgag 3000
gggtgggtgc tctgaagtgg agtgaagcct caagcccatg aatgccaccc cagtcatctc 3060
tgggtgcagc tgctgctgtg gcccagcag gttctcaaag ctcccaagtc ctccctacga 3120
cacagcccaa atgtgtaaat ggcactgttg cctgacagt gcatggaaag gacgttgga 3180
tccaattggc actccttctc ccttattcaa ttagggttt gatttgccct tcgccattgt 3240
ttccaaagat caaggaatgt caataacatt ttaaaggacc aataaacagc ctccataaaa 3300
gtaaacctct tcccgtggaa gcacactcta ctactaaagg gaaggccctt gggctctgat 3360
ttgtcctttg cattgagaac ggtgtgggga tcagtgtgtg tgtatgtgat ttgtttattg 3420
agttggcttt gcttttttag ttttctttt aaaaataaaa tccttcttcc ccatgttact 3480
aaattaattt atgtttttga gaggttgagt ctcaaagtgt aaacaataaa cctccattca 3540
taaggtggat gttgtaagct tgatgggtgt tgtgaaagt atttagcttt gaccactttt 3600
catcctacag cttcaatatc aaactggtta ggaaagccca gggggaaggg agggggcagg 3660
ggaggaggca attctgaatg aatgaatgga tttttgttg tttttgcatg ttttaatatag 3720
aagttccctt cgttccttgg gagatgatgg cctttgaata tgcagacaac ctttgaattg 3780
tgcctactaa attatagcag gggacttttg caccacaagga gttctgactt tctgggatta 3840
taatagtaat tcccagccat actctggact ttattttgct aaccataact gagcaaatgt 3900
aaattactgc tatattaatg ttttaagca ctgggatagt ctaattctaa cttgtaatta 3960
attatgtttg ccaattatct gtttgaaata aatttgtgtc tgaacagcta ttgaaactgt 4020

taaattgtac agatattatt catgacagct ttgtactgtg gaatgtgctt aataaaaaaac 4080
 aaaaaagttt gacttttgtc cagtaaattg ctaagtaatg tcaataaatc gagtatgggt 4140
 attatgcagt gcacctaatac tggcttcacg caattgttac ttcagctact gattcaaagc 4200
 caataactctt aataaagtgt tgcaataactc 4230

<210> 16

<211> 542

<212> PRT

<213> Homo sapiens

<400> 16

Met Glu Pro Asp Ser Val Ile Glu Asp Lys Thr Ile Glu Leu Met Cys
 1 5 10 15

Ser Val Pro Arg Ser Leu Trp Leu Gly Cys Ala Asn Leu Val Glu Ser
 20 25 30

Met Cys Ala Leu Ser Cys Leu Gln Ser Met Pro Ser Val Arg Cys Leu
 35 40 45

Gln Ile Ser Asn Gly Thr Ser Ser Val Ile Val Ser Arg Lys Arg Pro
 50 55 60

Ser Glu Gly Asn Tyr Gln Lys Glu Lys Asp Leu Cys Ile Lys Tyr Phe
 65 70 75 80

Asp Gln Trp Ser Glu Ser Asp Gln Val Glu Phe Val Glu His Leu Ile
 85 90 95

Ser Arg Met Cys His Tyr Gln His Gly His Ile Asn Ser Tyr Leu Lys
 100 105 110

Pro Met Leu Gln Arg Asp Phe Ile Thr Ala Leu Pro Glu Gln Gly Leu
 115 120 125

Asp His Ile Ala Glu Asn Ile Leu Ser Tyr Leu Asp Ala Arg Ser Leu
 130 135 140

Cys Ala Ala Glu Leu Val Cys Lys Glu Trp Gln Arg Val Ile Ser Glu
 145 150 155 160

Gly Met Leu Trp Lys Lys Leu Ile Glu Arg Met Val Arg Thr Asp Pro
 165 170 175

Leu Trp Lys Gly Leu Ser Glu Arg Arg Gly Trp Asp Gln Tyr Leu Phe
 180 185 190

Lys Asn Arg Pro Thr Asp Gly Pro Pro Asn Ser Phe Tyr Arg Ser Leu
 195 200 205

Tyr Pro Lys Ile Ile Gln Asp Ile Glu Thr Ile Glu Ser Asn Trp Arg
 210 215 220

Cys Gly Arg His Asn Leu Gln Arg Ile Gln Cys Arg Ser Glu Asn Ser
 225 230 235 240

Lys Gly Val Tyr Cys Leu Gln Tyr Asp Asp Glu Lys Ile Ile Ser Gly
 245 250 255
 Leu Arg Asp Asn Ser Ile Lys Ile Trp Asp Lys Thr Ser Leu Glu Cys
 260 265 270
 Leu Lys Val Leu Thr Gly His Thr Gly Ser Val Leu Cys Leu Gln Tyr
 275 280 285
 Asp Glu Arg Val Ile Val Thr Gly Ser Ser Asp Ser Thr Val Arg Val
 290 295 300
 Trp Asp Val Asn Thr Gly Glu Val Leu Asn Thr Leu Ile His His Asn
 305 310 315 320
 Glu Ala Val Leu His Leu Arg Phe Ser Asn Gly Leu Met Val Thr Cys
 325 330 335
 Ser Lys Asp Arg Ser Ile Ala Val Trp Asp Met Ala Ser Ala Thr Asp
 340 345 350
 Ile Thr Leu Arg Arg Val Leu Val Gly His Arg Ala Ala Val Asn Val
 355 360 365
 Val Asp Phe Asp Asp Lys Tyr Ile Val Ser Ala Ser Gly Asp Arg Thr
 370 375 380
 Ile Lys Val Trp Ser Thr Ser Thr Cys Glu Phe Val Arg Thr Leu Asn
 385 390 395 400
 Gly His Lys Arg Gly Ile Ala Cys Leu Gln Tyr Arg Asp Arg Leu Val
 405 410 415
 Val Ser Gly Ser Ser Asp Asn Thr Ile Arg Leu Trp Asp Ile Glu Cys
 420 425 430
 Gly Ala Cys Leu Arg Val Leu Glu Gly His Glu Glu Leu Val Arg Cys
 435 440 445
 Ile Arg Phe Asp Asn Lys Arg Ile Val Ser Gly Ala Tyr Asp Gly Lys
 450 455 460
 Ile Lys Val Trp Asp Leu Gln Ala Ala Leu Asp Pro Arg Ala Pro Ala
 465 470 475 480
 Ser Thr Leu Cys Leu Arg Thr Leu Val Glu His Ser Gly Arg Val Phe
 485 490 495
 Arg Leu Gln Phe Asp Glu Phe Gln Ile Ile Ser Ser Ser His Asp Asp
 500 505 510
 Thr Ile Leu Ile Trp Asp Phe Leu Asn Val Pro Pro Ser Ala Gln Asn
 515 520 525

Glu Thr Arg Ser Pro Ser Arg Thr Tyr Thr Tyr Ile Ser Arg
530 535 540

<210> 17
<211> 2151
<212> DNA
<213> Homo sapiens

<400> 17
tgcgttggct gcggcctggc accaaagggg cggccccggc ggagagcgga cccagtggcc 60
tcggcgatta tggacccggc cgaggcgggtg ctgcaagaga aggcactcaa gtttatgaat 120
tcctcagaga gagaagactg taataatggc gaaccccccta ggaagataat accagagaag 180
aattcactta gacagacata caacagctgt gccagactct gcttaaacca agaaacagta 240
tgtttagcaa gcaactgctat gaagactgag aattgtgtgg ccaaaacaaa acttgccaat 300
ggcacttcca gtatgattgt gcccaagcaa cggaaactct cagcaagcta tgaaaaggaa 360
aaggaaactgt gtgtcaaata ctttgagcag tggtcagagt cagatcaagt ggaatttgtg 420
gaacatctta tatcccaaat gtgtcattac caacatgggc acataaactc gtatcttaaa 480
cctatgttgc agagagattt cataactgct ctgccagctc ggggattgga tcatatcgct 540
gagaacattc tgtcacacct ggatgccaaa tcactatgtg ctgctgaact tgtgtgcaag 600
gaatggtacc gagtgcctc tgatggcatg ctgtggaaga agcttatcga gagaatggtc 660
aggacagatt ctctgtggag aggcctggca gaacgaagag gatggggaca gtatttattc 720
aaaaacaaac ctctgacgg gaatgctct cccaactctt tttatagagc actttatcct 780
aaaattatac aagacattga gacaatagaa tctaattgga gatgtggaag acatagttaa 840
cagagaattc actgccgaag tgaaacaagc aaaggagttt actgtttaca gtatgatgat 900
cagaaaatag taagcggcct tcgagacaac acaatcaaga tctgggataa aaacacattg 960
gaatgcaagc gaattctcac aggccataca gggtcagtc tctgtctcca gtatgatgat 1020
agagtgatca taacaggatc atcggattcc acggtcagag tgtgggatgt aaatacaggt 1080
gaaatgctaa acacgttgat tcaccattgt gaagcagttc tgcacttgcg tttcaataat 1140
ggcatgatgg tgacctgctc caaagatcgt tccattgctg tatgggatat ggcctcccca 1200
actgacatta ccctccggag ggtgctggtc ggacaccgag ctgctgtcaa tgtttagtag 1260
tttgatgaca agtacattgt ttctgcatct ggggatagaa ctataaaggt atggaacaca 1320
agtacttgtg aatttgtaag gaccttaaat ggacacaaac gaggcattgc ctgtttgcag 1380
tacagggaca ggctggtagt gagtggctca tctgacaaca ctatcagatt atgggacata 1440
gaatgtggtg catgtttacg agtggttagaa ggccatgagg aattggtgag ctgtattcga 1500
tttgataaca agaggatagt cagtggggcc tatgatggaa aaattaaagt gtgggatctt 1560
gtggctgctt tggacccccg tgcctctgca gggacactct gtctacggac ccttgtggag 1620
cattccggaa gagtttttcg actacagttt gatgaattcc agattgtcag tagttcacat 1680
gatgacacaa tctcatctg ggacttccta aatgatccag ctgcccgaagc tgaaccccc 1740
cgttccccct ctcgaacata cacctacatc tcagataaaa taaccataca ctgacctcat 1800
acttgcccag gaccatttaa agttgcggta tttaacgtat ctgccaatac caggatgagc 1860
aacaacagta acaatcaaac tactgccag tttccctgga ctagccgagg agcagggctt 1920
tgagactcct gttgggacac agttggtctg cagtggcccc aggacggtct actcagcaca 1980
actgactgct tcagtgtctg tatcagaaga tgtcttctat caattgtgaa tgattggaac 2040
ttttaaacct cccctcctct cctcctttca cctctgcacc tagttttttc ccattggttc 2100
cagacaaagg tgacttataa atatatttag tgttttgcca gaaaaaaaa a 2151

<210> 18
<211> 569
<212> PRT
<213> Homo sapiens

<400> 18
Met Asp Pro Ala Glu Ala Val Leu Gln Glu Lys Ala Leu Lys Phe Met
1 5 10 15

Asn Ser Ser Glu Arg Glu Asp Cys Asn Asn Gly Glu Pro Pro Arg Lys
 20 25 30
 Ile Ile Pro Glu Lys Asn Ser Leu Arg Gln Thr Tyr Asn Ser Cys Ala
 35 40 45
 Arg Leu Cys Leu Asn Gln Glu Thr Val Cys Leu Ala Ser Thr Ala Met
 50 55 60
 Lys Thr Glu Asn Cys Val Ala Lys Thr Lys Leu Ala Asn Gly Thr Ser
 65 70 75 80
 Ser Met Ile Val Pro Lys Gln Arg Lys Leu Ser Ala Ser Tyr Glu Lys
 85 90 95
 Glu Lys Glu Leu Cys Val Lys Tyr Phe Glu Gln Trp Ser Glu Ser Asp
 100 105 110
 Gln Val Glu Phe Val Glu His Leu Ile Ser Gln Met Cys His Tyr Gln
 115 120 125
 His Gly His Ile Asn Ser Tyr Leu Lys Pro Met Leu Gln Arg Asp Phe
 130 135 140
 Ile Thr Ala Leu Pro Ala Arg Gly Leu Asp His Ile Ala Glu Asn Ile
 145 150 155 160
 Leu Ser Tyr Leu Asp Ala Lys Ser Leu Cys Ala Ala Glu Leu Val Cys
 165 170 175
 Lys Glu Trp Tyr Arg Val Thr Ser Asp Gly Met Leu Trp Lys Lys Leu
 180 185 190
 Ile Glu Arg Met Val Arg Thr Asp Ser Leu Trp Arg Gly Leu Ala Glu
 195 200 205
 Arg Arg Gly Trp Gly Gln Tyr Leu Phe Lys Asn Lys Pro Pro Asp Gly
 210 215 220
 Asn Ala Pro Pro Asn Ser Phe Tyr Arg Ala Leu Tyr Pro Lys Ile Ile
 225 230 235 240
 Gln Asp Ile Glu Thr Ile Glu Ser Asn Trp Arg Cys Gly Arg His Ser
 245 250 255
 Leu Gln Arg Ile His Cys Arg Ser Glu Thr Ser Lys Gly Val Tyr Cys
 260 265 270
 Leu Gln Tyr Asp Asp Gln Lys Ile Val Ser Gly Leu Arg Asp Asn Thr
 275 280 285
 Ile Lys Ile Trp Asp Lys Asn Thr Leu Glu Cys Lys Arg Ile Leu Thr
 290 295 300

Gly His Thr Gly Ser Val Leu Cys Leu Gln Tyr Asp Glu Arg Val Ile
 305 310 315 320
 Ile Thr Gly Ser Ser Asp Ser Thr Val Arg Val Trp Asp Val Asn Thr
 325 330 335
 Gly Glu Met Leu Asn Thr Leu Ile His His Cys Glu Ala Val Leu His
 340 345 350
 Leu Arg Phe Asn Asn Gly Met Met Val Thr Cys Ser Lys Asp Arg Ser
 355 360 365
 Ile Ala Val Trp Asp Met Ala Ser Pro Thr Asp Ile Thr Leu Arg Arg
 370 375 380
 Val Leu Val Gly His Arg Ala Ala Val Asn Val Val Asp Phe Asp Asp
 385 390 395 400
 Lys Tyr Ile Val Ser Ala Ser Gly Asp Arg Thr Ile Lys Val Trp Asn
 405 410 415
 Thr Ser Thr Cys Glu Phe Val Arg Thr Leu Asn Gly His Lys Arg Gly
 420 425 430
 Ile Ala Cys Leu Gln Tyr Arg Asp Arg Leu Val Val Ser Gly Ser Ser
 435 440 445
 Asp Asn Thr Ile Arg Leu Trp Asp Ile Glu Cys Gly Ala Cys Leu Arg
 450 455 460
 Val Leu Glu Gly His Glu Glu Leu Val Arg Cys Ile Arg Phe Asp Asn
 465 470 475 480
 Lys Arg Ile Val Ser Gly Ala Tyr Asp Gly Lys Ile Lys Val Trp Asp
 485 490 495
 Leu Val Ala Ala Leu Asp Pro Arg Ala Pro Ala Gly Thr Leu Cys Leu
 500 505 510
 Arg Thr Leu Val Glu His Ser Gly Arg Val Phe Arg Leu Gln Phe Asp
 515 520 525
 Glu Phe Gln Ile Val Ser Ser Ser His Asp Asp Thr Ile Leu Ile Trp
 530 535 540
 Asp Phe Leu Asn Asp Pro Ala Ala Gln Ala Glu Pro Pro Arg Ser Pro
 545 550 555 560
 Ser Arg Thr Tyr Thr Tyr Ile Ser Arg
 565

<210> 19

<211> 6

<212> PRT

<213> Homo sapiens

<400> 19

Asp Ser Gly Leu Asp Ser
1 5

<210> 20

<211> 20

<212> PRT

<213> Homo sapiens

<400> 20

Ala Ala Val Asn Val Val Asp Phe Asp Asp Lys Tyr Ile Val Ser Ala
1 5 10 15

Ser Gly Asp Arg
20

<210> 21

<211> 17

<212> PRT

<213> Homo sapiens

<400> 21

Glu Leu Phe Pro Leu Ile Phe Pro Ala Glu Pro Ala Gln Ala Ser Gly
1 5 10 15

Pro

<210> 22

<211> 10

<212> PRT

<213> Homo sapiens

<220>

<221> MOD_RES

<222> (6)

<223> PHOSPHORYLATION

<220>

<221> MOD_RES

<222> (10)

<223> PHOSPHORYLATION

<400> 22

Cys Asp Arg His Asp Ser Gly Leu Asp Ser
1 5 10

<210> 23

<211> 4

<212> PRT
<213> Homo sapiens

<400> 23
Val Val Asn Val
1

<210> 24
<211> 17
<212> PRT
<213> Homo sapiens

<400> 24
Ala Ala Val Asn Val Val Asp Phe Asp Asp Lys Tyr Ile Val Ser Ala
1 5 10 15

Ser

<210> 25
<211> 9
<212> PRT
<213> Homo sapiens

<400> 25
Leu Glu Gly His Glu Glu Leu Val Arg
1 5

<210> 26
<211> 12
<212> PRT
<213> Homo sapiens

<400> 26
Leu Val Val Ser Gly Ser Ser Asp Asn Thr Ile Arg
1 5 10

<210> 27
<211> 12
<212> PRT
<213> Homo sapiens

<400> 27
Ile Gln Asp Ile Glu Thr Ile Glu Ser Asn Trp Arg
1 5 10

<210> 28
<211> 9
<212> PRT
<213> Homo sapiens

<400> 28
Val Ile Ser Glu Gly Met Leu Trp Lys
1 5

<210> 29
<211> 10
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (5)
<223> PHOSPHORYLATION

<220>
<221> MOD_RES
<222> (9)
<223> PHOSPHORYLATION

<400> 29
Asp Arg His Asp Ser Gly Leu Asp Ser Met
1 5 10

<210> 30
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> MOD_RES
<222> (2)
<223> PHOSPHORYLATION

<220>
<221> MOD_RES
<222> (6)
<223> PHOSPHORYLATION

<400> 30
Asp Ser Gly Leu Asp Ser
1 5